An Open-label, Multi-center, Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy
Phase: PHASE3
Conditions: Epilepsy
Sponsor: UCB PHARMA Inc. (US)

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 1 of 72
1
TITLE
PROTOCOL N01199
An open-label, multicenter, follow-up trial to evaluate the long-term safety and efficacy of 
brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day 
in subjects aged 16 years or older suffering from epilepsy.
Sponsor:
UCB Pharma Inc.
1950 Lake Park Drive
USA - GA 30080
Smyrna
UNITED STATES
Hereafter “UCB”
Brivaracetam - IND Number: 70,205
Confidential Material
“The information contained in this document is strictly confidential. It is disclosed to you as a 
(potential) Investigator or (potential) consultant. Acceptance of this document constitutes 
your agreement that the information contained herein will not be disclosed or in anyway 
communicated to any third party without prior written approval of the Sponsor (or its 
representative(s) of the clinical study described therein except - to the extent necessary - to 
your staff, to members of appropriate review committee(s) and/or to persons to whom the 
investigational product may be administered or to their legal representative(s) to obtain their 
informed consent.”
REDACTED 
m
DA
m -
AC
- IN
C
IN
COPY 
E
Y
E
“UCB
COP
“UCB
This document
pr
t
pr
yo
men
your 
ent 
ur 
in
me
in
canno
reem
ot 
reem
munic
nno
munic
resen
ca
resen
be
Inve
be 
Inve
me
b
me
used
ater
d 
ater
tion c
used
tion c
es
u
es
to 
ria
to
ria
support any marketing authorization 
B”
o
B”
N
ut
ND
uth
D N
ho
N
application and any extensions
mg
ns 
mg
or 
y
or
y o
r
o
g
o
g/d
or
/d
variations 
of 
va
of 
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 2 of 72
Protocol Signatures:
Authorized signature on behalf of UCB:
Principal Investigator
“By my signature below, I acknowledge that I have read the protocol RPCE05C2110 and 
agree that it contains all necessary details for carrying out the clinical study described therein. 
Furthermore, I agree to conduct this clinical study in compliance with said Protocol, the ICH 
Good Clinical Practice guideline, as well as with any and all applicable federal, state and/or 
local laws and regulations and with my contractual obligations towards the Sponsor of the 
clinical study or its representatives(s).”
Signature:
__________________________________
Date:
_________
Printed Name:
__________________________________
Address:
__________________________________
__________________________________
Phone:
__________________________________
Site Number:
_________
REDACTED
___
ED 
___
COPY 
__
Y
__
____
OPY
____
____
CO
____
C
This document cannot be used to support any marketing authorization 
____
on
____
_____
atio
_____
application 
Date:
ation
Date:
_
pl
_
____
ap
___
and 
 th
d
 th
any
dera
ny 
dera
he Sp
any
he Sp
extensions 
10
io
10 an
ons
an
crib
ens
cribed
nsi
ed
rotoco
exte
rotoco
al
e
al
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 3 of 72
2
CONTACT INFORMATION
Sponsor
UCB Pharma Inc.
1950 Lake Park Drive
USA - GA 30080
Smyrna
UNITED STATES
Study Physician
Name:
, MD
Phone:
Fax:
Clinical Project Manager
Name:
Phone:
Fax:
Safety Physician
Name:
, MB BCh 
BAO, MRCGP
Phone:
Fax:
Clinical Trial Statistician
Name:
Phone:
Fax:
REDACTED
Fa
ED 
Fa
BCh
REDA
BCh
COPY 
hone:
COP
hone:
ax
C
ax
This document cannot be used to support any marketing authorization 
:
P
u
P
applicatioion 
d
and any 
a
extensions or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 4 of 72
SAE Reporting (24h/24), Safety Related Issues (GCSP)
Email:
Global:
DSICT@ucb.com
Fax:
Europe and Rest of the World:
USA: 
+32-2-386-2421+1-
800-880-6949
Canada:
+1-877-582-8842
Investigator(s)
The complete and updated list of Investigators is maintained in the Trial Master File (TMF) at 
the sponsor.
REDACTED COPY 
Y
This document cannot be used to support any marketing authorization application 
d in the
plica
d in the
and any 
ns 
9
s
9
extensions
2
o
2-884
ons
-884
or r variations 
+1
v
1-
va
-
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 5 of 72
3
TABLE OF CONTENTS
1
TITLE..............................................................................................................................1
2
CONTACT INFORMATION .......................................................................................3
3
TABLE OF CONTENTS...............................................................................................5
4
LIST OF ABBREVIATIONS........................................................................................9
5
PROTOCOL SUMMARY...........................................................................................12
5.1
Study Schedule of Assessments.......................................................................18
5.2
Schematic Diagram ..........................................................................................21
6
BACKGROUND INFORMATION............................................................................23
6.1
Background and epidemiology of targeted disease..........................................23
6.2
Background information regarding product.....................................................24
6.3
Efficacy with BRV in fixed-dose Phase II/III studies in POS .........................25
6.4
Safety with BRV ..............................................................................................25
6.5
Study Rationale ................................................................................................26
6.5.1
Dose Selection....................................................................................26
6.5.2
Subjects Population............................................................................26
6.5.2.1
Minimal Age...............................................................26
6.5.3
Duration of Treatment........................................................................26
7
STUDY OBJECTIVES ................................................................................................27
7.1
Primary Objective ............................................................................................27
7.2
Secondary Objectives.......................................................................................27
7.3
Exploratory Objectives.....................................................................................27
8
STUDY DESIGN ..........................................................................................................28
8.1
Type/Design .....................................................................................................28
8.2
Subjects/Sites Numbers....................................................................................29
8.3
Subject Identifier..............................................................................................29
8.4
Study Duration .................................................................................................29
8.5
End of Study.....................................................................................................29
9
SELECTION AND WITHDRAWAL OF SUBJECTS.............................................29
9.1
Subject Inclusion Criteria.................................................................................29
9.2
Subject Exclusion Criteria................................................................................30
9.3
Subject Withdrawal..........................................................................................30
9.3.1
Withdrawal Criteria............................................................................31
9.3.2
Subject Replacement Policy...............................................................32
10
TREATMENT OF SUBJECTS (INVESTIGATIONAL PRODUCT AND 
CONCOMITANT MEDICATIONS) .........................................................................32
10.1
Study Investigational Products.........................................................................32
10.1.1
Description of all Investigational Products........................................32
REDACTED 
....
D
....
......
TE
......
inimal
ACT
inimal
AC
eatme
EDA
eatme
ED
.
R
.
COPY 
......
PY
......
..
CO
......
CO
....
..
C
..
This document cannot
ELE
ot 
ELE
ot
9.1
nn
9.1
n
9.
can
9.
be 
EC
b
EC
d
bj
d
bj
d
use
Study
sed 
Study
se
End
us
End
u
to
ect 
to 
ect 
t
upport 
.......
ort 
.......
s
sign
ppo
sign .
p
.
pp
ts/Site
sup
ts/Site
s
I
s
Id
s
d
any
ectiv
ny 
ectiv
ny marketing 
........
ting
........
.......
rke
.......
ves
ma
ves...
a
...
m
ve
m
ve
authorization 
...
n
...
......
tio
......
......
riz
......
l Age
thor
l Age
th
ent
au
nt..
au
..
au
application 
..
n
..
........
tio
........
studies
icat
studies
lic
........
pp
........
..
a
..
and 
.......
nd
.......
..
a
..
any
.....
ny 
.....
extensions 
........
ons
........
.........
ens
.........
......
ex
......
e
or
.....
or 
.....
variations 
.3
ari
.3
ar
v
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 6 of 72
10.1.2
Dosing Schedule ................................................................................32
10.1.3
Packaging...........................................................................................33
10.1.4
Labeling..............................................................................................33
10.1.5
Storage Requirements ........................................................................33
10.1.6
Monitoring of Subject Compliance....................................................34
10.1.7
Investigational Products Accountability ............................................34
10.2
Concomitant Treatments and Rescue Medications..........................................35
10.2.1
Permitted Concomitant Treatments (Medications and Therapies) ....35
10.2.2
Prohibited Concomitant Treatments (Medications and 
Therapies)...........................................................................................35
11
STUDY PROCEDURES..............................................................................................35
11.1
Description of Procedures ................................................................................35
11.1.1
Informed Consent...............................................................................35
11.1.2
Subject Study Card.............................................................................36
11.1.3
Demography.......................................................................................36
11.1.4
Childbearing Potential and Birth Control ..........................................36
11.1.5
General Medical and Procedure History............................................36
11.1.6
Epilepsy History.................................................................................36
11.1.7
Antiepileptic Medication History.......................................................36
11.1.8
Vital Signs..........................................................................................36
11.1.9
Weight and Height .............................................................................37
11.1.10 Physical Examination.........................................................................37
11.1.11 Neurological Examination .................................................................37
11.1.12 ECG....................................................................................................37
11.1.13 Daily Record Card (DRC)..................................................................38
11.1.14 Laboratory Assessments.....................................................................38
11.1.15 Adverse Events (AEs)........................................................................39
11.1.16 Assessment of Suicidality ..................................................................39
11.1.17 Medical Procedures............................................................................40
11.1.18 Non-Antiepileptic and Antiepileptic Concomitant Medications........41
11.1.19 Patient Reported Outcomes................................................................41
11.1.20 Quality of Life in Epilepsy Questionnaire (QOLIE-31-P).................41
11.1.21 Hospital Anxiety and Depression Scale (HADS) ..............................42
11.1.22 EQ-5D Questionnaire.........................................................................42
11.1.23 Hospital Stay......................................................................................42
11.1.24 Healthcare Provider Consultation not Foreseen by Protocol.............43
11.1.25 Socio-professional Data .....................................................................43
11.1.26 End of Study.......................................................................................43
11.2
Description Visit by Visit.................................................................................44
11.2.1
Entry Visit..........................................................................................44
11.2.2
Full Evaluation Visit ..........................................................................45
11.2.3
Minimal Evaluation Visit...................................................................46
11.2.4
Yearly Evaluation Visit (replaces the first FEV of each year)...........46
REDACTED
..
D
..
ation H
TED 
ation H
TE
......
ACT
......
ight
EDAC
ight
ED
amina
RED
amina
R
E
R
E
COPY
irth 
PY 
irth 
PY
edure 
COPY
edure 
O
...
C
...
This document cannot be 
d
11.1.1
sed 
11.1.1
use
se
se
11.
us
11.
u
to 
.18
to
.18
to
ppor
vers
ort 
vers
ort
Asse
ppo
Asse
supp
ss
o
ss
pp
7
s
7 Med
sup
Med
s
N
s
N
any
atory
any 
atory
y
y
y
y
an
se E
a
se E
ng
tion
g 
tion
marketing
ng
Examin
keting
Examin
ket
........
ark
........
ord C
ma
ord C
m
A
authorization 
H
n
H
n
......
tio
......
Histor
rizat
Histor
iz
......
ho
......
......
au
......
n
a
n
application 
.
........
tio
........
.......
ca
.......
Control
pplic
Control
pp
Histor
app
Histor
a
and 
......
d
......
....
a
....
any
.......
any 
.......
.
extensions 
.....
s
.....
apies)
sions
apies)
io
........
exte
........
or 
..
r
..
.....
or
.....
variations 
34
ari
34
ar
..34
va
.34
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 7 of 72
11.2.5
Early Discontinuation Visit................................................................47
11.2.6
Down-Titration Phone Call................................................................48
11.2.7
Final Visit (FV following a Study Drug Free Period after an 
EDV or FV initiated upon Sponsor request at the end of the 
program).............................................................................................48
11.2.8
Additional Visit..................................................................................49
11.3
Handling of Biological Samples ......................................................................49
11.4
Other Supplies..................................................................................................49
12
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS...................................49
12.1
Adverse Events.................................................................................................49
12.1.1
Definition of Adverse Event (AE) .....................................................49
12.1.2
Procedures for Reporting and Recording Adverse Events.................50
12.1.3
Description of AEs.............................................................................50
12.1.4
Follow-up on Adverse Events............................................................53
12.1.5
Rule for Repetition of an AE .............................................................53
12.1.6
Pregnancy...........................................................................................53
12.1.7
Overdose of Investigational Product..................................................54
12.2
Serious Adverse Events....................................................................................54
12.2.1
Definition of Serious Adverse Event (SAE)......................................54
12.2.2
Procedures for Reporting Serious Adverse Events (SAE).................55
12.2.3
Anticipated Serious Adverse Events..................................................56
13
STATISTICS.................................................................................................................56
13.1
Statistical and Analytical Plans........................................................................56
13.1.1
Study Population(s)............................................................................56
13.1.2
Efficacy and Safety Variables............................................................56
13.1.3
Statistical Evaluation..........................................................................58
13.2
Determination of the Sample Size....................................................................60
13.3
Statistical and Analytical Issues.......................................................................60
13.3.1
Handling of Dropouts of Missing Data..............................................60
13.3.2
Interim Analysis and Data Monitoring ..............................................60
13.3.3
Use of an Efficacy Subset of Subjects ...............................................60
13.3.4
Examination of Subgroups.................................................................60
13.4
Criteria for Starting the Analysis .....................................................................60
13.5
Dictionaries ......................................................................................................61
14
ETHICS AND REGULATORY REQUIREMENTS................................................61
14.1
Approval...........................................................................................................61
14.2
Subject Information and Consent.....................................................................62
14.3
Subject Confidentiality.....................................................................................63
14.4
Informing the General Practitioner (or Pediatrician) .......................................64
15
STUDY MANAGEMENT AND ADMINISTRATION ............................................64
15.1
Monitoring........................................................................................................64
REDACTED
..
D
..
s Adve
TED 
s Adve
TE
eportin
ACTE
eportin
AC
rious A
EDAC
rious A
ED
...
R
...
COPY 
..
Y
.....
Y
...
al Prod
COPY
al Prod
O
...
C
...
This document 
4
nt
4
nt cannot 
.4
ot
.4
ot
13.5
nno
13.5
n
E
ca
E
be used 
.3.
d
.3.
d
13.3.
sed
13.3.
us
13
u
13
to 
1
o
1
o
.2
to
.2
support
s
t
s
t
tion o
port 
tion o
po
al a
upp
al and 
ppo
nd 
up
Ha
su
Ha
any 
y
n
y an
y
an
ny
ical E
any
ical E
a
f
marketing 
.
t
........
ting
.......
cal Pla
keti
cal Pla
ke
ulation
mark
ulation
ma
nd S
m
nd S
authorization 
du
n
du
n
......
tio
......
erse E
rizat
erse E
iz
ng Ser
thoriz
ng Ser
ho
Adver
auth
Adver
au
application 
.
........
tio
........
..........
icati
..........
.......
pp
.......
uct...
app
uct...
a
and
erse 
nd 
erse 
nd
....
a
....
any 
......
ny
......
Ev
a
Ev
extensions 
...
s
.....
s
..
......
io
......
.........
tens
.........
.....
ex
.....
or 
..
r
..
.....
or
.....
variations 
48
ari
48
ar
..49
va
.49
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 8 of 72
15.2
Direct Access to Source Data/Documents .......................................................64
15.3
Audit and Inspection ........................................................................................65
15.4
Case Report Forms (CRF)................................................................................65
15.5
Adherence to Protocol......................................................................................66
15.6
Investigator Site File ........................................................................................67
15.7
Data Handling ..................................................................................................67
15.8
Termination of Study .......................................................................................67
15.8.1
Termination of Study by Sponsor ......................................................68
15.9
Clinical Study Report.......................................................................................68
15.10
Insurance and Liability.....................................................................................68
15.11
Archiving and Data Retention..........................................................................68
15.12
Allocation of Responsibilities..........................................................................69
15.13
Curriculum Vitae (CV).....................................................................................69
15.14
Financial Disclosure.........................................................................................69
15.15
Good Clinical Practice .....................................................................................70
15.16
Publication........................................................................................................70
16
REFERENCES .............................................................................................................70
17
SPONSOR DECLARATION ......................................................................................72
List of Tables
Table 5:1
Study Flowchart...........................................................................................18
Table 5:2
Visit Schematic Diagrams ...........................................................................22
EDACTED 
......
D 
......
List o
ACT
List o
RED
.......
ED
.......
iagra
RE
iagra
R
COPY 
.
Y
.
......
OP
......
This document cannot be used to support any marketing
.
rams ..
ting 
rams ..
tin
authorization 
...
n
...
......
ati
......
f Tab
tho
f Tab
a
....
a
....
lication 
......
on 
......
.......
at
.......
appli
.......
plic
.......
....
a
....
and 
..
d
..
......
an
......
any 
....
y
....
.....
a
.....
extensions 
.....
s
.....
........
ions
........
.........
ensi
.........
.
e
........
exte
.......
or 
.
r
..
r
.
.....
or
.....
variations 
67
ari
67
ar
..67
va
.67
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 9 of 72
4
LIST OF ABBREVIATIONS
AE(s)
Adverse Event(s)
AED(s)
Antiepileptic Drug(s)
ALT 
(ALAT/SGPT)
Alanine Aminotransferase
ASAT/SGOT
Aspartate Aminotransferase
ALP
Alkaline Phosphatase
AV
Additional Visit
b.i.d.
Twice Daily
BRV
Brivaracetam
BZD
Benzodiazepine
CBZ
Carbamazepine
CDMS
Clinical Data Management System
CPMP
Committee for Proprietary Medicinal Product
Cr Cl
Creatinine Clearance
CRF
Case Report Form
CRO
Clinical Research Organization
C-SSRS
Columbia Suicide Severity Rating Scale
CTM
Clinical Trial Manager
CV
Curriculum Vitae
CYP
Cytochrome
DBP
Diastolic blood pressure
DHHS
Department of Health and Human Services
dl
Deciliter
DRC
Daily Record Card
DTP
Down-titration Phone Call
ECG
Electrocardiogram
EDV
Early Discontinuation Visit
EQ-5D
EuroQoL 5 Dimensions Questionnaire
ER
Emergency room
EV
Entry Visit
FEV
Full Evaluation Visit
FDA
Food and Drug Administration
FV
Final Visit
GCP
Good Clinical Practice
GCSP
Global Clinical Safety and Pharmacovigilance
GGT
Gamma-glutamyltranspeptidase
GMP
Good Manufacturing Practices
GP
General Practitioner
h
Hour
HADS
Hospital Anxiety and Depression Scale
REDACTED
ganiz
ED 
ganiz
Severi
CTE
Severi
anage
DAC
anage
V
R
Vitae
REDA
itae
COPY 
d
Y
d
za
C
za
This document
V
t
V
GC
ent 
GC
G
e
G
cannot 
A
V
c
V
be used to support 
y
t
y
own
port
own-t
E
up
Elect
pp
lect
E
su
E
any 
r
ny
r
R
an
Reco
any
eco
marketing 
od pre
rket
od pre
nt of H
mar
nt of H
authorization 
ation
zatio
ation
rity
ori
rity Ra
oriza
Ra
y
ori
y
er
ut
er
application 
al Prod
plica
al Prod
and any extensions or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 10 of 72
HDPE
High Density Polyethylene
IB
Investigator Brochure
ICH
International Conference on Harmonization
IEC
Independent Ethics Committee
ILAE
International League Against Epilepsy
IND
Investigational New Drug
IRB
Institutional Review Board
IVRS
Interactive voice response system
IWRS
Interactive web response system
kg
Kilogram
L
Liter
LTG
Lamotrigine
m
Meter
MCH
Mean Corpuscular Haemoglobin
MCHC
Mean Corpuscular Haemoglobin Concentration
MCV
Mean Corpuscular Volume
MedDRA
Medical Dictionary for Regulatory Activities
MEV
Minimal Evaluation Visit
µg
Microgram
mg
Milligram
min
Minute
ml
Milliliter
µL
Microliter
µM
Micromol
PBO
Placebo
PGS
Primary Generalized Epilepsy
PK
Pharmacokinetics
POS
Partial Onset Seizure
PRO
Patient Reported Outcomes
QOLIE-31-P
Patient Weighted Quality of Life in Epilepsy Questionnaire
RBC
Red Blood Cell
SAE
Serious Adverse Event
SAP
Statistical Analysis Plan
SAS
Statistical Analysis System
SBP
Systolic blood pressure
SDV
Source Data Verification
SOC
System Organ Class
SOP
Standard Operating Procedure
SP
Study Physician
SV2A
Synaptic Vesicle Protein 2A
TMF
Trial Master File
WBC
White Blood Cell
WHO
World Health Organization
REDACTED COPY
gulator
OPY 
gulator
t
C
t
This document 
SD
t
SD
SO
en
SO
cannot 
P
a
P
DV
ca
DV
be used to 
ort 
rm
rt
rm
suppo
artial 
port
artial 
Patie
supp
Patie
P
s
P
any
y
an
y Ge
any 
Ge
y y
an
y y
maco
an
maco
marketing 
en
m
authorization application 
entrati
atio
entrati
ry
a
y A
app
Acti
pp
cti
and any extensions or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 11 of 72
YEV
Yearly Evaluation Visit
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 12 of 72
5
PROTOCOL SUMMARY
Investigational Product:
Brivaracetam (BRV)
Objectives:
Primary Objective
To evaluate the long-term safety and tolerability of BRV at individualized doses with a 
maximum of 200 mg/day in subjects suffering from epilepsy.
Secondary Objective
To evaluate the maintenance of efficacy over time of BRV (for POS/PGS subjects).
Exploratory Objectives

To explore the effects of BRV on the subject’s Health-related Quality of Life, anxiety,
and depression for the first 2 years.

To explore medical resource use and indirect cost parameters for the first 2 years.

To obtain a description of the subject’s self-reported health status for the first 2 years.

To explore any change in the subject’s socio-professional status for the first 2 years.
This study will provide subjects suffering from epilepsy, who may benefit from BRV as 
adjunctive treatment, the opportunity to receive open label adjunctive BRV treatment.  
Conversion to monotherapy is not permitted anymore; however, subjects already on 
monotherapy are allowed to continue BRV monotherapy.  The access will be limited to the 
subjects having completed a previous BRV study as listed in Section 5.2.
Estimated Number of Subjects, Sites and Rationale:
It is estimated that approximately 500 - 1,000 subjects will enter the study based on the 
assumption that 90% of subjects having completed a previous study with BRV as adjunctive 
treatment in epilepsy will roll over into the present study.
It is estimated that between 100 - 200 sites will participate in this global protocol.
Subject Population and Diagnosis:
Before any study procedures are initiated for any subject in this study, an Independent Ethics
Committee (IEC)/Institutional Review Board (IRB) approved written informed consent form 
will be properly executed and documented.
Subject Inclusion Criteria:

An IEC/IRB approved written informed consent signed and dated by the subject or by 
parent(s) or legally acceptable representative. The consent form or a specific assent form, 
where required, will be signed and dated by minors.
REDACTED
lf
ED
lf-
ED
-f-f
ED
f-f rep
ED 
rep
AC
socio
CTE
socio
fering 
RED
fering 
R
to
R
to
R
COPY 
al
Y
al
cost 
CO
cost 
C
This document 
efo
t
efo
Com
ment
Com
w
m
w
cannot t
ject
cann
ject P
n
P
fore
ca
ore
be
ated t
be 
ated t
used
leps
ed
lepsy
d 
y
to
% o
to 
% o
t
support 
Subjec
ppor
Subjec
proxim
supp
proxim
of s
s
of s
any
revio
any 
revio
ng
fro
g 
fro
market
o receiv
eting
o receiv
ermitte
arke
ermitte
nue B
ma
nue B
m
authorization
para
tion 
para
ported
izatio
ported
o
h
o-
o
-prof
horiz
prof
om
au
om
application 
elated
plica
elated
a
and
/PGS 
and 
/PGS 
any extensions 
 with
ensi
 with
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 13 of 72

Male/female subjects from 16 years or older. Subjects under 18 years may only be 
included where legally permitted and ethically accepted.

Subjects with epilepsy who participated in previous BRV studies which allow access to 
the present study.

Subjects from whom the Investigator believes a reasonable benefit from the long-term 
administration of BRV may be expected.

Female subjects without childbearing potential (premenarcheal; 2 years postmenopausal 
bilateral oophorectomy or ovariectomy, bilateral salpingectomy, complete hysterectomy, 
congenital sterility) are eligible. Female subjects with childbearing potential are eligible 
if they use a medically accepted contraceptive method for the duration of the study (Intra 
Uterine Device, diaphragm with spermicide, male or female condom with spermicide; 
oral hormonal contraceptive, non-oral hormonal contraceptive medication, bilateral tubal 
ligation, bilateral tubal implant, monogamous relationship with vasectomized partner). 
Oral or depot contraceptive treatment with at least 30 µg [or 50 µg if associated with 
other antiepileptic drugs (AEDs) known as inducers] ethinylestradiol per intake must be 
used in conjunction with a barrier method. The subject must understand the consequences 
and potential risks of inadequately protected sexual activity, be educated about and 
understand the proper use of contraceptive methods, and undertake to inform the 
Investigator of any potential change in status. According to the judgment of the 
Investigator, sexual inactivity might be accepted on a case-by-case basis. 

Subject/legally acceptable representative considered as reliable and capable of adhering to 
the protocol (e.g. able to understand and complete diaries and questionnaires), visit 
schedule or medication intake according to the judgment of the Investigator.
Subject Exclusion Criteria:

Severe medical, neurological and psychiatric disorders or laboratory values which may 
have an impact on the safety of the subject.

Poor compliance with the visit schedule or medication intake in the previous BRV study.

Participation in any clinical study of another investigation drug or device during the 
study.

Pregnant or lactating woman.
Drug Administration: 
Subjects coming from BRV studies have the opportunity to access BRV treatment at a 
flexible dose of up to a maximum of 200 mg/day in b.i.d. administration. It is recommended 
that the daily dose be divided equally and be taken with or without food. The first intake will 
be in the evening of the day of the dispensation of the study medication. The individual 
starting dose of each subject will be the one defined/reached at the end of the previous study.
At each visit, an interactive voice response system (IVRS) /interactive web response system 
(IWRS) will be responsible for issuing subjects kits of study medication, as appropriate, 
according to the visit schedule and according to the supplies needed by the subject in terms of 
the number of tablets of each size (80 count or 200 count), and of each dosage (10 mg and 25 
REDACTED
atus
TED
atus.
D 
.
e acce
ACTE
e acce
ntative
DAC
ntative
and an
RED
and an
co
R
co
COPY 
ubje
Y
ubje
exual a
OPY
exual a
ethod
CO
ethod
This document
hat t
nt 
hat t
be i
men
be i
m
nnot 
dm
t
dm
cts 
nn
cts com
not
com
ca
xible d
can
ible d
th
c
th
be 
minis
be
minis
used
r lacta
sed 
r lacta
to support
safet
ort 
safet
th the v
ppo
th the v
ny
su
ny clin
sup
clin
y
su
y
any
cal an
any 
cal an
ety
a
ety o
a
o
y
a
y
marketing
and c
ng 
and c
ording t
eting
ording t
d
authorization
c
ds,
tion
ds, an
on 
an
Acco
izati
Acco
epted 
horiz
epted 
e cons
auth
e cons
co
au
co
application
50 µg
tion 
50 µg
yl
ca
ylestra
catio
estra
t must u
pplic
t must u
ctivity
app
ctivity
d
and 
di
d
dica
d
ca
vasec
and
vasec
a
any
with 
ny 
with 
ation
an
ation
extensions
opau
ns 
opau
terect
sion
terect
al are 
tens
al are 
f f the 
exte
the 
e
e
or 
usa
o
usa
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 14 of 72
mg tablets) according to the dose prescribed and the possibility to down-titrate/up-titrate by a 
maximum of 50 mg/day steps on a weekly basis. In case of study drug discontinuation, a last 
down-titration step at 20mg/day for 1 week will be included prior to the study-drug free 
period.  Containers of 80 tablets will be progressively removed.
Oral tablets of 10 mg and 25 mg BRV will be used in this study. Initially, BRV 2.5 mg and 
10 mg tablets were packaged in blister cards containing 20 tablets each. Visit cartons of 80 
(4 blister cards) and 200 (10 blister cards) tablets were provided and each visit carton had a 
unique, pre-printed identification number.
In November 2006, a transition from blister cards to HDPE (High Density Polyethylene) 
bottles was implemented. Brivaracetam 2.5 mg oral tablets were packaged in bottles of 200 
tablets and BRV 10 mg oral tablets were packaged in bottles of 80 and 200 tablets. Each 
bottle has a unique, pre-printed identification number. Containers of 80 tablets will be 
progressively removed.
HDPE bottles containing 80 and 200 oral tablets of BRV 25 mg will be available when 
subjects begin enrolling from BRV Phase III studies (N01252, N01253, and N01254).  
Containers of 80 tablets will be progressively removed.
Each subject will be informed on how to take the drug and that there is an excess of drug in 
the visit carton or bottle.
Methodology:
This is a Phase III, therapeutic long-term follow-up, multicenter, non-comparative, open-label 
and single arm study.
This study will run throughout the duration of the clinical development period of BRV and 
will thus include the therapeutic exploratory study completed during the early stage of 
development as well as therapeutic confirmatory studies which will be completed in the later 
stages of development.  For this reason, the study design of this study and in particular the 
frequency of study visits is adapted for the 2 types of phases as described below.
For those subjects coming from the therapeutic exploratory study, visits will be scheduled as 
follows:

First year:

During the first 6 months there will be 1 visit/month; 1 Full Evaluation Visit 
(FEV) alternating with 1 Minimal Evaluation Visit (MEV).

During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7
and V8).

Second and subsequent years:

1 visit every 3 months; 1 FEV alternating with 1 MEV.
REDACTED
rem
ED 
rem
o take 
DACT
o take 
COPY
BRV
OPY 
BRV
dies (N
COP
dies (N
mov
C
mov
This document t canno
se su
ot 
se su
ws:
nn
ws:
Firs
ca
Firs
be 
ubj
b
ubj
used
pme
ed 
pme
study
used
tudy
to
ll as
to 
ll as
ent
to
ent
support
ghout 
port 
ghout 
herapeu
upp
herapeu
as th
su
as th
any marketing 
ng
m
ng-t
ma
-term
ar
erm
authorization
N012
ion 
N012
oved.
zatio
oved.
e the d
utho
e the d
application
s of 
on 
s of 
25 mg
app
25 mg
25
a
25
and
age
d
age
nd 20
and 
nd 20
f 80
a
f 80
any
Pol
ny 
Pol
ed in
any
ed in
extensions 
of 
s
of 
ton ha
sions
ton ha
oly
e
oly
or 
and
or
and
f 80
or
f 80
variations 
nd
v
d
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 15 of 72

The Yearly Evaluation Visit (YEV) will be performed in replacement of the first 
FEV of each year.
For those subjects coming from therapeutic confirmatory studies:

First year:

First 3 months: 1 visit/month: FEV alternating with MEV.

Next 9 months: 1 visit/3 months: FEV alternating with MEV.

Second and subsequent years:

1 visit/3 months: FEV alternating with MEV.

The YEV will be performed in replacement of the first FEV of each year.
Variables and Assessments:
The efficacy variables will be assessed by using the seizure count information recorded on the 
DRC.  The subject will be asked to record the date and the number (where possible) of 
epileptic seizures he/she has experienced.  The type of seizure (according to individual 
description of seizures) will be defined by the Investigator by adding the ILAE codes.  The 
Investigator will also confirm on the DRC the number of seizures of each type experienced 
by the subject.
The periods considered in the definition of efficacy variables are the following:

3-month periods over the Evaluation Period (V1 until the last evaluation visit).
Primary safety variables:

Occurrence of a TEAE

Withdrawal due to an AE

Occurrence of an SAE
Other safety variables:

Laboratory tests (hematology, blood chemistry, urinalysis)

Vital signs (systolic blood pressure [SBP]), diastolic blood pressure [DBP], pulse rate) 
and body weight

Electrocardiogram (ECG)

Physical and neurological examinations
REDACTED 
of effic
ACTE
of effic
on P
EDAC
on Per
AC
er
COPY
igato
PY 
igato
mber o
COPY
mber o
This document cannot 
ab
t
ab

V
nn
V
be 
borat
be
borat
used
riable
sed 
riable
se
to 
of
of
support
an A
ort 
an A
f an S
sup
f an S
any 
AE
AE
marketing authorization 
of 
n
of 
cacy v
thoriz
cacy v
riod (V
auth
riod (V
application
nf
n
ber (w
tion 
ber (w
e (acco
icati
e (acco
b
p
by 
ppl
y add
plic
add
seizu
app
seizu
and 
form
and
form
any y extensions 
ach
ext
ach y
x
y
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 16 of 72

Change in Hospital Anxiety and Depression Scale (HADS) scores from the Baseline 
of the previous study to each assessment for the first 2 years and to the last Evaluation 
Period assessment during the first 2 years
Secondary efficacy variables
POS (type I) frequency per 28 days during the Evaluation Period
Percent reduction in POS (type I) frequency per 28 days from Baseline of the previous 
study to the Evaluation Period
Responder rate for POS (type I) frequency over the Evaluation Period. A responder is
defined as a subject with a ≥50% reduction in seizure frequency from the Baseline 
Period of the previous study
Other efficacy variables
For subjects with focal-onset epilepsy:
Percentage of subjects continuously seizure-free for all seizure types (I+II+III) for at 
least 6 months and at least 12 months during the Evaluation Period
For subjects with generalized epilepsy:
Generalized (type II) seizure days per 28 days during the Evaluation Period
Percent reduction in generalized (type II) seizure days per 28 days from Baseline of the 
previous study to the Evaluation Period
Responder rate for generalized (type II) seizure days over the Evaluation Period. A 
responder is defined as a subject with a ≥50% reduction in seizure days from the 
Baseline Period of the previous study
Percentage of subjects continuously seizure-free for all seizure types (I+II+III) for at 
least 6 months and at least 12 months during the Evaluation Period
The following will be evaluated separately for subjects with focal-onset epilepsy and subjects 
with generalized epilepsy:
Change in Patient Weighted Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)
scores from Baseline of the previous study to each assessment for the first 2 years and 
to the last Evaluation Period assessment during the first 2 years
REDACTED 
ure
ED
ure-
D
-
s durin
CTED
s durin
y
RE
y:
E
:
COPY 
fr
C
fr
This document
with 
nt 
with 
nt cannot 
st 6
t
st 6
 follo
cann
 follo
ca
h g
ca
h g
be 
ntag
e
ntag
6 m
be
6 m
used 
rio
d
rio
age o
us
age o
o
ef
o
od o
to 
od o
support t
r gener
uppo
r gener
fined a
sup
ined a
f
any 
aliz
y
aliz
aluati
any
aluati
marketing 
ay
k
ays per 
ketin
s per 
ized 
m
ized 
authorization 
free fo
zatio
free fo
ng the
oriza
ng the
application and 
fro
d
fro
any
od. A
any 
od. A
om th
an
om th
extensions 
he pre
ensio
he pre
A
e
A
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final /15 Oct 2015 / Page 17 of 72
EuroQol 5 Dimensions (EQ-5D) questionnaire response for each assessment for the first 
2 years for the Evaluation Period and for the last assessment during the first 2 years of 
the Evaluation Period
Pharmacoeconomic variables
The following will be evaluated separately for subjects with focal-onset epilepsy and subjects
with generalized epilepsy:
Direct costs (healthcare provider consultations not foreseen by the protocol, concurrent 
medical procedures, concomitant medications, hospitalizations, and emergency room 
[ER] visits) during the first 2 years of the Evaluation Period
Indirect costs (work days or school days lost by the subject and days subject received 
help from a caregiver) during the first 2 years of the Evaluation Period
Socio-professional data for each assessment for the first 2 years and for the last 
assessment during the first 2 years of the Evaluation Period
REDACTED COPY 
This document cannot be used to support any marketing authorization 
lication 
2 y
ati
2 y
applic
ears
ation
ears
eriod
lica
eriod
and
d
nd
day
nd
ays
d 
s
n Per
and
n Per
any 
s su
an
s su
extensions 
l, con
ensio
l, con
ergenc
exten
ergenc
o
bjec
or 
bjec
variations 
cts
v
cts
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 18 of 72
5.1
Study Schedule of Assessments
Table 5:1
Study Flowchart
Entry 
Visit
(EV)
Full 
Evaluation 
Visit 
(FEV)
Minimal 
Evaluation 
Visit 
(MEV)
Yearly 
Evaluation 
Visit 
(YEV)
Additional 
Visit
(AV)
Early 
Discontinuation 
Visit
(EDV) (a) 
Down-Titration 
Phone Call
(DTP) (a) 
Final Visit
(FV)
Reference to 
Section
ASSESSMENTS
Written Informed Consent
X
11.1.1
Clinical Trial Subject Card 
Dispensing
X
11.1.2
Verification Inclusion/ 
Exclusion Criteria
X
9.1 and 9.2
Demographic Data
X
11.1.3
Childbearing Potential
X
11.1.4
Medical and Procedures History
X(b) 
11.1.5
Epilepsy History
X(b) 
11.1.6
AED History
X(b) 
11.1.7
Vital Signs
X(c) 
X
X
X
X
X
X
11.1.8
Weight and Height(d) 
X
X
X
X
X
11.1.9
Physical Examination
X(c) 
X
X
X
X
11.1.10
Neurological Examination
X(c) 
X
X
X
X
11.1.11
ECG(e) 
X(c) 
X
X
X
11.1.12
Daily Record Card Dispensed
X
X
X
X
X
11.1.13
Daily Record Card Retrieval
X
X
X
X
X
X
11.1.13
Recording of Seizures
X (c) 
X
X
X
X
X
11.1.13
QOLIE-31-P(f) (k)
X
X
X
11.1.20
HADS(f) (k)
X
X
X
11.1.21
REDACTED 
ED
AC
DA
ED
RE
COPY 
PY
O
CO
This document cannot 
ot
anno be 
X
e
X (
e
(
be used 
d 
ed
sed
ed
ed
ed
ed
(c) 
u
c) 
us
to 
to support 
rtrtrtrt
ort
X
u
X
pp
su
any 
X
y 
X
ny marketing 
g
tin
et
rk
X
m
X
m
authorization 
n
at
riz
ho
u
a
application 
iscon
on 
iscon
V
n
V
ic
licicicic
pp
a
and 
Early
and
Early
nti
a
nti
nd any extensions or variations 
C
a
C
5 Oct
va
5 Oct
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 19 of 72
Table 5:1
Study Flowchart (continued)
Entry 
Visit
(EV)
Full 
Evaluation 
Visit
(FEV)
Minimal 
Evaluation 
Visit 
(MEV)
Yearly 
Evaluation 
Visit
(YEV)
Additional 
Visit
(AV)
Early 
Discontinuation 
Visit(a) 
(EDV)
Down-Titration 
Phone Call
(DTP) (a) 
Final Visit
(FV)
Reference to 
Section
EQ-5D(g) (k)
X
X
X
11.1.22
Workdays and schooldays lost / 
days with caregiver’s help (k)
X
X
X
X
X
X
11.1.13
Hospital Stay (k)
X
X
X
X
X
X
11.1.23
Heathcare Provider Consultations
not foreseen by the protocol (k)
X
X
X
X
X
X
11.1.24
Socio-professional Data(h) (k)
X
X
11.1.25
Laboratory Assessments(i) 
X(c) 
X
X
X
X
11.1.14
Recording of Adverse Events
X
X
X
X
X
X
X
X
11.1.15
C-SSRS(l)
X
X
X
X
X
X
11.1.16
Medical Procedures
X
X
X
X
X
X
X
11.1.17
Concomitant AED
X
X
X
X
X
X
X
11.1.18
Concomitant Non-AED
X
X
X
X
X
X
X
11.1.18
Drug Dispensing
X
X
X
X
X
10.1.2 and 
10.1.6
Drug Return/Accountability
X
X
X
X
X
10.1.6 and 
10.1.7
End of Study Status(j) 
X
11.1.26
REDACTED 
X
CTE
X
TE
AC
ED
ED
ED
ED
RE
COPY 
PY
CO
CO
CO
CO
CO
This document cannot be used to support t
po
pp
s
any 
X
ny
X
y
a
marketing 
X
g
X
X
g
X
g
eti
ke
rk
X
m
X
ma
m
authorization 
X
n
X
X
o
X
n
iz
ori
X
tho
X
a
X
au
application 
(ED
n
(ED
X
n
X
n
at
pli
pp
and 
a
d
a
sit
an
sit(a) 
nd
(a) 
DV
a
DV
any 
ion
an
ion
y extensions 
e
or variations 
C
a
C
5 Oct
va
5 Oct
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 20 of 72
Table 5:1
Study Flowchart (continued)
AED=antiepileptic drug; AV=Additional Visit; CRF=Case Report Form; C-SSRS=Columbia Suicide Severity Rating Scale; DTP=Down-titration Phone 
Call; ECG=electrocardiogram; EDV=Early Discontinuation Visit; EV=Entry Visit; FEV=Full Evaluation Visit; FV=Final Visit; HADS=Hospital Anxiety 
and Depression Scale; MEV=Minimal Evaluation Visit; QOLIE-31-P=Patient Weighted Quality of life in Epilepsy Questionnaire; YEV=Yearly 
Evaluation Visit
(a) Down-Titration phone call at the end of the down-titration period is mandatory in case the subjects discontinue from more than 20mg/day BRV.
(b) The following data will be transferred from the database of the baseline visit of the previous study and should not be recorded into the CRF:  General 
Medical and Procedure History, AED History and Epilepsy History.
(c) The following data will be transferred from the database of the last visit of the previous study and should not be recorded in the CRF:  Vital Signs, 
Physical Examination, Neurological Examination, ECG, Recording of seizures, Laboratory Assessment including Safety (blood chemistry, hematology 
and urinalysis) 
(d) Height will be recorded at Visit 1 (Entry Visit).  Height will also be measured at each YEV and the Final Visit for those subjects that are still potentially 
growing.
(e) At Final Visit, ECG is mandatory except if Final Visit follows an Early Discontinuation Visit where ECG results were normal.
(f) QOLIE-31-P and HADS are to be completed at the beginning of the visit by all subjects (except those coming from N01193) who are not mentally 
impaired.
(g) EQ-5D questionnaire is to be completed by all subjects (except those coming from N01193) who are not mentally impaired.
(h) Socio-professional data will be collected for all subjects except those coming from N01193.
(i) Laboratory assessment includes blood chemistry, hematology and urine analysis; where applicable (women of childbearing potential), a urine pregnancy 
test will be done. Laboratory assessment is mandatory at Final visit except if Final Visit follows an Early Discontinuation Visit where laboratory results 
were normal.
(j) End of study status will be completed at the FV for subjects having performed an EDV (discontinued subjects) and for subjects leaving the study at the 
end of the program (completed subjects).
(k) Procedures only performed during the first 2 years of subject participation in the study (eg, until last scheduled visit [Y3-YEV]) or EDV/FV in case the 
subject discontinues participation within the first 2 years).
(l) The C-SSRS assessment will be implemented by site per IRB/IEC approval and upon completion of required training.  As of the time of Protocol Amendment 6, all 
subjects had completed their Entry Visit.  Thus, the C-SSRS was not assessed for any subjects at their Entry Visit.
(m) For subjects that may transition to another BRV study or a managed access program or similar type of program, the EDV will need to be completed, however 
down-titration and FV may not be applicable.
REDACTED
res
ED
res, 
D
, L
D 
L
measu
ACT
measu
an
RE
an E
ED
Ear
D
ar
of th
RE
of th
COPY 
e pre
Y
e pre
e prev
COP
e prev
Lab
C
Lab
This document 
ot 
to a
ot
to a
cann
be app
nno
be app
be
sit.  T
be 
sit.  T
anot
be
anot
used
n the f
ed 
n the f
mented
use
mented
Thu
u
Thu
to
st 2
to
st 2 y
o 
y
i
t
i
support 
y at 
rt
y at 
V for su
upp
V for su
any
tology
any 
tology
Fina
an
Fina
marketing 
rly
g
rly
he visit
ting
he visit
ept thos
mark
ept thos
xcept t
ma
cept t
authorization 
ious 
on
ious 
borator
atio
borator
ured at 
thor
ured at 
D
au
Dis
au
is
application 
ubjects 
icat
ubjects 
ous
ppli
ous stud
plic
stud
stu
a
t
and
n Vis
nd 
n Vis
 in Ep
an
in Ep
any 
ty Rati
any
ty Rati
it;
a
it;
extensions or variations 
C
a
C
5 Oct
va
5 Oct
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 21 of 72
5.2
Schematic Diagram
For subjects coming from the therapeutic exploratory study (N01193), visits will be 
scheduled as follows:

First year:

During the first 6 months there will be 1 visit/month; 1 Full Evaluation Visit 
(FEV) alternating with 1 Minimal Evaluation Visit (MEV).

During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7
and V8).

Second and subsequent years:

1 visit every 3 months; 1 FEV alternating with 1 MEV.

The Yearly Evaluation Visit (YEV) will be performed in replacement of the first 
FEV of each year.
For those subjects coming from therapeutic confirmatory studies (N01252, N01253, and 
N01254):

First year:

First 3 months: 1 visit/month: FEV alternating with MEV.

Next 9 months: 1 visit/3 months: FEV alternating with MEV.

Second and subsequent years:

1 visit/3months: FEV alternating with MEV.

The YEV will be performed in replacement of the first FEV of each year.
REDACTED 
FEV a
TED
FEV a
nths:
ACT
nths:
R
altern
RE
altern
COPY
tory
PY 
tory
This document cannot be used to support any marketing
nating
ing 
nating
med in 
ketin
med in 
authorization 
altern
rizat
altern
FEV
thor
FEV
a
application 
tudies
pplic
tudies
and 
n repl
and
n repl
any extensions 
Visit 
ns
Visit 
EV (at 
tens
EV (at 
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 22 of 72
Table 5:2
Visit Schematic Diagrams
Subjects coming from Exploratory Study
(N01193)
Subjects coming from Confirmatory 
Studies (N01252, N01253, N01254)
1st Year Follow-up
1st Year Follow-up
Month
Visit
Type of Visit
Month
Visit
Type of Visit
M0
V1
Entry Visit
M0
V1
Entry Visit
M1
V2
MEV
M1
V2
MEV
M2
V3
FEV
M2
V3
FEV
M3
V4
MEV
M3
V4
MEV
M4
V5
FEV
M4
M5
V6
MEV
M5
M6
V7
FEV
M6
V5
FEV
M7
M7
M8
M8
M9
V8
FEV
M9
V6
MEV
M10
M10
M11
M11
2nd and subsequent years follow-up
2nd and subsequent years follow-up
M12
V9
YEV
M12
V7
YEV
M15
V10
MEV1
M15
V8
MEV1
M18
V11
FEV
M18
V9
FEV
M21
V12
MEV2
M21
V10
MEV2
In case the subject will not continue with the study drug, the Investigator will first plan an 
Early Discontinuation Visit followed by the progressive down-titration of the study drug.  
During the down-titration period, the dose may be decreased in steps of a maximum of
50 mg/day on a weekly basis. A last down-titration step at 20mg/day for 1 week will be 
included prior to the study drug free period.
At the end of the down-titration period, a phone call will be given to subjects having down-
titrated from doses higher than 20 mg/day. The down-titration period will be followed by a 
period free of study drug of a minimum of 2 weeks and a maximum of 4 weeks and 
subsequently, the Final Visit will occur.
When the time point is reached at which the study will be terminated by the sponsor (as 
defined in Section 8.4), subjects will discontinue the study drug, following the Investigator’s 
instructions for down-titration if necessary.
REDACTED 
D
T D
T
CT
E
up
EDA
up
AC
V
R
V
ED
1
R
1
R
COPY 
M
Y
M
M
PY
M
PY 
O
C
This document
subse
ent 
subse
m
nnot 
d 
t
d 
d from
nnot
d from
ca
iod fr
can
od fr
c
be 
of th
be
of th
d 
ee
d
ee
use
to the
sed
to the
to
a
ekl
to
ekly
o 
y
support
t con
ort 
t con
Visit fo
uppo
Visit fo
at
s
tion p
sup
ion p
y
M
y
M
any y
ntin
a
ntin
marketing 
g 
ng
EV
ar
EV
ke
ma
ME
m
EV2
ma
V2
ma
authorization 
8
M9
tion
M9
n
M
zat
M
tio
riz
th
th
tho
a th
a
application 
tio
ca
plic
pp
a
and 
d
a
any y
ny extensions 
e of V
sions
e of V
ns
Entry
ensi
Entry
isio
ten
ex
or 
or variations 
ar
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 23 of 72
6
BACKGROUND INFORMATION
6.1
Background and epidemiology of targeted disease
Epilepsy is one of the most common and challenging neurological disorders.  It has been 
estimated that over 50 million people are affected worldwide (Engel and Pedley, 1998; 
Hauser et al, 1993; Loiseau et al, 1990; Sander and Shorvon, 1996).  The prevalence of 
epilepsy is around 1%. The annual incidence in developed countries is approximately 50 to 
70 cases per 100.000.  In developing countries, the figure is higher due to more limited 
obstetric services and the greater likelihood of cerebral infection and trauma.  The incidence 
varies greatly with age, with high rates occurring in childhood, falling to low levels in early 
adult life, but with a second peak in those aged over 65 years.  In many people, particularly 
children, the condition may remit, although a significant proportion will have epilepsy 
lifelong.  The disease duration is often determined by the underlying cause.  Sudden 
unexpected death, a complication of great concern, occurs in 1 to 5 per 1000 patient years, 
particularly if the seizure disorder remains uncontrolled.  The treatment for epilepsy remains 
difficult, and there is ongoing medical need for new antiepileptic drugs (AEDs).  For 
considerable proportions of patients, seizure freedom can still not be reached with currently 
available AEDs (Nasreddine et al, 2010; Kwan and Brodie, 2001).
Diagnosis of epilepsy is based on the recurrence of seizures.  Seizures may be caused by an 
underlying brain disorder or lesion or due to genetic conditions.  Characterization of the 
epileptic syndrome has profound implications for treatment and prognosis.  The major 
dichotomy for the diagnosis of epilepsy is the differentiation between focal epilepsies (ie, 
related to a focal brain dysfunction), which are the most frequent and account for 
approximately 60 to 70% of all cases, and generalized epilepsy syndromes, which represent 
approximately 25 to 30% of all epilepsy syndromes.  In about 10% of cases, other specific 
syndromes are classified or the classification remains uncertain.
The classification of epileptic syndromes and seizure types is – and always was – a matter of 
ongoing debate.  First published in 1960 and last updated officially in 1981 for seizures and 
1989 for epilepsies (Commission on Classification and Terminology of the International 
League Against Epilepsy ([ILAE], 1981 and 1989), these ILAE classifications were based on 
concepts that, for the most part, predate modern technologies and concepts (Engel, 2006)
ILAE (http://www.ilae-epilepsy.org).  The availability of these modern techniques, like long-
term video electroencephalograms (EEGs) and high-resolution magnetic resonance imaging 
(MRI), providing much more precise knowledge in regard to seizure type classifications and 
epileptic syndromes, led some epilepsy groups and scientists towards introducing competing 
classification systems (like the Cleveland Clinic Epilepsy Classification) and even debating 
how useful the currently used ILAE classification system is at all (Lüders et al, 2006).
This ongoing debate regarding the classification systems for epilepsies and seizures is also 
reflected within the latest Report of the Commission on Classification and Terminology 
REDACTED
an an
ED 
an an
curren
DACT
curren
r due t
REDA
r due t
plic
RE
plic
COPY
ed
Y
ed
w antie
OPY 
w antie
dom c
COP
dom c
nd
C
nd
This document
rm
t
rm
(MR
ment 
(MR
ep
me
ep
no
s tha
ot 
s tha
cann
E (
an
E (http
anno
http
m vid
ca
m vid
be
gains
be 
gains
at
b
at
used
 Fir
ed 
 Fir
psies 
used
psies 
st
u
st
to
of ep
to 
of ep
rst
to
rst
support
f al
t
f al
or the 
port 
or the
epile
su
epile
any
case
ny 
case
ll epi
any
ll epi
marketing 
to 
g
to 
cations
ting
cations
psy
rke
psy is t
ket
is t
y
ke
y
n), wh
mar
n), wh
ses
m
ses
authorization
can s
ion 
can s
d Brod
zatio
d Brod
nce of
utho
nce of
o gen
au
gen
application
i
o
ing c
on 
ng c
to
ati
to 5
tio
5 p
o
p
he treat
plica
he treat
epilept
app
pilept
sti
a
sti
and
y p
d
y p
will h
and 
will h
ca
a
ca
any
ow l
ny 
ow l
eople
any
eople
extensions 
of 
ns
of 
tely
sion
tely 50
ons
50
y
on
y
limite
ensi
limite
e
The 
exte
The 
lev
e
lev
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 24 of 72
(Classification Task Force) which proposes a thoroughly revised terminology and concept for 
the diagnosis of epilepsy syndromes and also to some extent seizure types (Berg et al, 2010). 
Despite this ongoing debate, for the purpose of this study, the seizure type classification will 
follow the 1981 ILAE classification of epileptic seizures, which speaks of partial seizures, 
classified as simple partial seizures (no alteration of consciousness), complex partial seizures 
(with alteration of consciousness), and secondarily generalized seizures, and on the other 
hand defines generalized seizure types, referred to as absence seizures (typical and atypical), 
myoclonic seizures, clonic seizures, tonic seizures, tonic-clonic seizures, and atonic seizures.  
Apart from myoclonic seizures, consciousness is almost invariably impaired from the onset of 
the seizure (Commission on Classification and Terminology of the ILAE, 1981).
Likewise, the classification of epilepsy syndromes will be used according to the 1989 ILAE-
publication (Commission on Classification and Terminology of the ILAE, 1989).
6.2
Background information regarding product
Brivaracetam is a 2-pyrrolidone derivative. Like levetiracetam (LEV, Keppra®), BRV
displays a high and selective interaction with a novel brain-specific binding site, SV2A 
(synaptic vesicle protein 2A).  However, the binding affinity of BRV for SV2A is 
approximately 10-fold higher than with LEV.  This binding site appears to be the major target 
for its pharmacological activity.  Unlike LEV, BRV also reduces voltage-dependent sodium 
currents.  Brivaracetam also reverses the inhibitory effects of negative allosteric modulators 
on gamma-aminobutyric acid, and glycine-induced currents.  Brivaracetam is extensively 
metabolized, but seizure protection appears to be associated with the parent compound.
Brivaracetam is rapidly and completely absorbed throughout the gastrointestinal tract.  The 
extent of BRV absorption is not affected by food.  The pharmacokinetics (PK) are 
dose-proportional (at least from 10 mg to 600 mg).  Brivaracetam is weakly bound to plasma 
proteins (≤20%).  The volume of distribution is 0.5 L/kg, a value that is close to that of total 
body water.  The plasma half-life of BRV is approximately 8 hours in young healthy male 
adults.  The main metabolic pathway of BRV is by hydrolysis of the acetamide group to the 
corresponding carboxylic acid, while a second pathway is the ω1-hydroxylation mediated by 
CYP2C19 (with contributions of several other isoenzymes).  The combination of these 
2 pathways results in the hydroxyacid terminal metabolite.  These metabolites are not 
pharmacologically active.  There is no evidence of chiral inversion of BRV.  Brivaracetam is 
eliminated primarily by metabolism and by excretion in the urine.  More than 95% of the 
dose, with less than 9% as unchanged BRV, is excreted in urine within 72 hours after dosing.
Pharmacokinetic studies in elderly subjects and in subjects with renal impairment showed a 
similar PK profile of BRV compared to that in healthy subjects, while the elimination of the 
metabolites was markedly slowed down.  A PK study in subjects with hepatic impairment 
showed a 50% increase in exposure to BRV associated with decreased hydroxylation.
REDACTED
a no
ED 
a no
he bind
CTE
he bind
LEV
DACT
LEV
CT
ike LE
REDA
ike LE
s the
RE
s the
COPY 
ct
Y
ct
levet
COP
levet
ve
C
ve
This document
har
t
har
elimi
ment 
elimi
do
me
do
anno
19 (w
ot 
19 (w
hway
anno
hway
c
o
rmac
ca
rmac
be
ding 
be 
ding 
(w
b
(w
used
e pla
ed 
e pla
main m
used
main m
ca
u
ca
to
The 
to 
The 
asm
to
asm
support
co
t
co
n is no
port 
n is no
east fr
upp
east fr
e vol
su
e vol
any 
ompl
any
ompl
marketing 
EV
g
EV
e inhib
ting
e inhib
ycine
rket
ycine
n appe
mar
n appe
authorization
tirac
ion 
tirac
vel bra
zatio
vel bra
ding a
oriza
ding a
.  This
utho
.  This
V,
au
V, B
u
B
application
he IL
on 
he IL
eta
a
eta
and
rding
and 
rding
LA
a
LA
any
198
ny 
198
extensions
ther
ns 
ther
at
io
atypi
ions
ypi
onic s
ensi
onic s
from 
exte
from 
81)
e
81)
or 
ure
or
ure
r
o
r
variations 
res
va
res
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 25 of 72
Brivaracetam does not impair the efficacy of oral contraceptives containing ethinylestradiol 
30 µg and levonorgestrel 150 µg.  Brivaracetam does not induce CYP3A4 using midazolam 
as a marker probe.  Brivaracetam has no interaction on lamotrigine (LTG) and topiramate.  
Brivaracetam plasma concentration is not increased by gemfibrozil, a selective CYP2C8/9 
inhibitor, but is increased in a nonclinically relevant manner in Japanese subjects possessing 
defective CYP2C19 mutations.  Brivaracetam clearance is doubled by rifampicin, a potent 
CYP inducer.
Trough levels of concomitant AEDs were monitored in all efficacy studies.  No significant 
change from Baseline nor dose-related trend was observed for the plasma concentrations of 
carbamazepine (CBZ), lamotrigine, LEV, oxcarbamazepine metabolite, phenobarbital, 
phenytoin, topiramate, valproate, and zonisamide. Carbamazepine epoxide was significantly 
increased from baseline at all BRV doses greater than 20 mg/day, nearly reaching the upper 
limit of normal (3.0 µg/mL) at BRV doses of 100 and 150 mg/day.
6.3
Efficacy with BRV in fixed-dose Phase II/III studies in POS
Following completion of the Phase II studies (N01114, UCB protocol reference code 
RPCE02K0301; N01193, UCB protocol reference code RPCE05C2201), clinical results 
supported further development of BRV for the adjunctive treatment of POS.  Two adequate 
and well-controlled fixed-dose studies (N01252, UCB protocol reference code 
RPCE06G0704; N01253, UCB protocol reference code RPCE06G0705) were conducted to 
assess BRV across a dose range of 5 to 100 mg/day.
N01253 assessed BRV doses of 5, 20, and 50 mg/day and provided statistically significant 
and clinically relevant evidence of the efficacy of BRV 50 mg/day.  N01252 assessed BRV
doses of 20, 50, and 100mg/day.  Although N01252 was not positive, it provided supporting 
evidence for the efficacy of BRV 100 mg/day in subjects with epilepsy.
6.4
Safety with BRV
In Phase II/III studies, a favorable safety and tolerability profile has been demonstrated for 
BRV.  The discontinuation rate and the discontinuation rate due to treatment-emergent 
adverse events (TEAEs) were low and similar to placebo (PBO) for all studies. The most 
frequently reported TEAEs were headache, somnolence, dizziness, and fatigue.  The overall 
incidence of serious adverse events (SAEs) was low and similar to PBO.  There were no 
clinically relevant changes in laboratory values, vital signs, or ECG abnormalities.
For additional details on safety and efficacy of BRV, please refer to the Investigator’s 
Brochure (UCB reference code RXCE06E2216).
REDACTED
(N01
ED 
(N01
ferenc
CTE
ferenc
for th
DACT
for th
es (N0
REDA
es (N0
ocol
RE
ocol
COPY
I/III 
OPY 
I/III 
11
C
11
This document
eq
t
eq
incid
ment 
incid
cl
me
cl
annot
The d
ot 
The d
rse ev
anno
rse ev
c
quen
ca
quen
be
/
b
/III
be
III s
 
s
di
b
di
used
with
ed 
with
st
u
st
to 
h
to
h B
o
B
support
enc
t
enc
mg/day
port 
mg/day
acy
up
acy of 
upp
of 
y
up
y
B
p
B
any
f 5, 2
ny 
f 5, 2
ce of
any
ce of
marketing 
012
g
012
ol refer
ting
ol refer
to 100
rket
to 100
20
m
20
authorization 
114
zati
114, U
atio
, U
ce cod
oriza
ce cod
he adju
utho
he adju
252
au
252
application
 nea
on 
 nea
/day
atio
/day.
studie
app
studie
and
, p
d
, p
epoxid
and 
poxid
arl
a
arl
any
conc
ny 
conc
p
a
pheno
any
heno
extensions
oten
ns 
oten
No sig
exte
No sig
nce
e
nce
or 
ing
or
ing
ent
or
ent
variations 
ng 
va
ng 
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 26 of 72
6.5
Study Rationale
The Sponsor wishes to develop BRV as an adjunctive antiepileptic treatment in subjects 
16 years and older suffering from epilepsy. N01199 will give subjects who have participated 
in previous BRV adjunctive treatment studies in epilepsy the opportunity to access adjunctive 
BRV treatment under the present protocol.  Conversion to monotherapy is not permitted
anymore; however, subjects already on monotherapy are allowed to continue BRV
monotherapy.
The subjects allowed to enter the study will mainly suffer from partial onset seizures (subjects 
coming from N01193, N01252, N01253, and N01254 [UCB protocol reference code 
RPCE06G0706]), while a minority will present with generalized epilepsy (subjects coming 
from N01254).  The N01252, N01253 and N01254 studies aimed to test the efficacy and 
tolerability of BRV in POS subjects as oral therapy. This study will explore the long-term 
safety and efficacy of BRV in such a population.
6.5.1
Dose Selection
In this study, individualized doses up to a maximum of 200 mg/day will be used. Twice daily 
dosing is deemed necessary to ensure more regular exposure over the 24-hour interval.
A maximum dose of 200 mg/day was chosen following consultation with regulatory 
authorities and is evaluated in more recent BRV studies (eg, N01358 and N01379).  
According to available data, 200 mg/day doses have been well tolerated.
6.5.2
Subjects Population
6.5.2.1
Minimal Age
Subjects are allowed to participate in this study from the age of 16 where legally permitted 
and ethically accepted. Indeed, epilepsy features in the range of 16 to 18 years do not differ 
from the ones of older subjects, and efficacy of the AEDs seems to be comparable
(CPMP/EWP/566/98 rev 1, 2000).
Depending on country-specific regulations, those subjects may be considered as adolescents 
or adults (CPMP/ICH/2711/99, 2000). In case they are considered as adolescents, parent(s) 
or legal representative will sign the informed consent form. The consent form or a specific 
assent form, where required, will be signed and dated by the minor.
6.5.3
Duration of Treatment
For each subject, the study will run throughout the duration of the clinical development 
period of BRV, and will continue until a marketing authorization is granted by any Health 
REDACTED
ximu
ED 
ximu
e regul
CTE
e regul
s chos
REDA
s chos
rece
RE
rece
COPY 
um
C
um
This document
a
t
a
or le
ment 
or le
as
me
as
cannot 
ending
anno
ending
adult
ca
dult
be
WP/5
be 
WP/5
used
cepte
ed 
cepte
of ol
used
of ol
56
u
56
to
d to
to 
d to
ted
to
ted
support 
to pa
su
to pa
any marketing 
sen
g
sen
ent BR
ting
ent BR
/day
rket
/day do
et
do
y
et
y
authorization 
m of 
zatio
m of 2
o
2
ular ex
oriza
ular ex
n fol
au
n fol
application
will e
on 
will e
and
ps
d
psy
d
y
test th
and 
test th
ex
a
ex
any
enc
ny 
enc
y (sub
any
y (sub
extensions 
seizur
exte
seizur
ce
e
ce
or variations 
ive
ari
ive
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 27 of 72
Authority in an indication for the adjunctive treatment in adults with refractory POS, whether 
or not secondarily generalized, until the Sponsor decides to close the study, until subjects 
transition to another BRV study, until a managed access program, named patient program, 
compassionate use program, or similar type of access program is established as allowed per 
country-specific requirement in addition to legal and regulatory guidelines, or until BRV 
development is stopped by the Sponsor.
Statement
The present study will be conducted in accordance with:

This protocol.

International Conference on Harmonization (ICH): ICH E6 Note for Guidance on Good 
Clinical Practice [CPMP/ICH/135/95] and Code of Federal Regulations on Good Clinical 
Practice (GCP) Title 21 Parts 50, 54, 56, 312 and 314).

The principles that have their origin in the Declaration of Helsinki.

All applicable local laws and regulations.
7
STUDY OBJECTIVES
7.1
Primary Objective
To evaluate the long-term safety and tolerability of BRV at individualized doses with a 
maximum of 200 mg/day in subjects suffering from epilepsy.
7.2
Secondary Objectives
To evaluate the maintenance of efficacy over time of BRV (for POS/PGS subjects).
7.3
Exploratory Objectives

To explore the effects of BRV on the subject’s Health-related Quality of Life, anxiety,
and depression for the first 2 years.

To explore medical resource use and indirect cost parameters for the first 2 years.

To obtain a description of the subject’s self-reported health status for the first 2 years.

To explore any change in the subject’s socio-professional status for the first 2 years.
REDACTED 
lerabi
DAC
lerabi
s suffe
RED
s suffe
COPY 
This document cannot
bta
t
bta
explo
nnot 
explo
be
ore
e
b
ain a
be 
ain a
used
ion
sed
ion f
d 
f
e
u
e me
use
me
to
effe
to 
effe
t
support 
Objectiv
ppor
Objectiv
ect
s
ect
any
f effi
any 
f effi
marketing
erin
g 
erin
ic
m
i
authorization 
ility
auth
ility o
tho
o
y
th
y
ng f
au
ng f
application 
lsink
ion 
lsinki
and 
tio
d
tio
i
a
i
any
Guid
ny 
Guid
ons o
any
ons o
extensions 
da
e
da
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 28 of 72
8
STUDY DESIGN
8.1
Type/Design
This is a Phase III, therapeutic, long-term, follow-up, multicenter, 
noncomparative, open-label, and single arm study.
The study design of this study and in particular the frequency of study visits is adapted for the 
2 types of studies as described below.
For those subjects coming from the therapeutic exploratory study (N01193), visits will be 
scheduled as follows:

First year:

During the first 6 months there will be 1 visit/month; 1 Full Evaluation Visit 
(FEV) alternating with 1 Minimal Evaluation Visit (MEV).

During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7 
and V8).

Second and subsequent years:

1 visit every 3 months; 1 FEV alternating with 1 MEV.

The Yearly Evaluation Visit (YEV) will be performed in replacement of the first 
FEV of each year.
For those subjects coming from therapeutic confirmatory studies (N01252, N01253, 
N01254):

First year:

First 3 months:  1 visit/month: FEV alternating with MEV.

Next 9 months: 1 visit/3 months: FEV alternating with MEV.

Second and subsequent years:

1 visit/3months: FEV alternating with MEV.

The Yearly Evaluation Visit will be performed in replacement of the first FEV of 
each year.
REDACTED
ternat
TED 
ternat
YEV)
ACTE
YEV)
ape
R
ape
COPY 
visi
Y
visi
This document cannot be used 
Yea
d
Yea
ch 
s
ch ye
sed
ye
to
m
arl
to
arly
o 
y
upport 
:
o
: 1 v
ort 
1 v
uent 
uppo
uent y
po
y
s
months
sup
onths
any
visit/m
any 
visit/m
vis
a
vis
marketing 
peutic
keting
peutic c
g
c
authorization 
ing w
izati
ing w
) will
horiz
) will
application
1 Fu
ion 
1 Fu
t (MEV
catio
t (MEV
very 3 
pplic
very 3 
and 
l
a
l
any 
)
ny
), v
ny 
, v
extensions 
pted f
sions
pted f
vis
e
vis
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 29 of 72
8.2
Subjects/Sites Numbers
It is estimated that approximately 500 - 1,000 subjects will enter the study based on the 
assumption that 90% of subjects having completed a previous study with BRV as adjunctive 
treatment in epilepsy will roll over into the present study.
It is estimated that between 100 - 200 sites will participate in the study.
8.3
Subject Identifier
Each subject will be identified by his/her initials and a subject identifier which include the 
study number, the site number and a sequential enrollment number.  The Master CRF number 
will be used as an additional identifier on laboratory reports and at the level of the database.
8.4
Study Duration
This study will run throughout the duration of the clinical development period of BRV, and 
will continue until a marketing authorization is granted by any Health Authority in an 
indication of the adjunctive treatment in adults with refractory POS, whether or not 
secondarily generalized, until the Sponsor decides to close the study, until subjects transition 
to another BRV study, until a managed access program, named patient program, 
compassionate use program, or similar type of access program is established as allowed per 
country-specific requirement in addition to legal and regulatory guidelines, or until BRV
development is stopped by the Sponsor.
8.5
End of Study
The end of the study is defined as the date of the last visit of the last subject in the study.
9
SELECTION AND WITHDRAWAL OF SUBJECTS
Before any study procedures are initiated for any subject in this study, an Independent Ethics 
Committee/Institutional Review Board (IEC/IRB) approved written informed consent form 
will be properly executed and documented.
9.1
Subject Inclusion Criteria
To be eligible to participate in this study, all of the following criteria must be met:

An IEC/IRB approved written informed consent signed and dated by the subject or by 
parent(s) or legally acceptable representative. The consent form or a specific assent form, 
where required, will be signed and dated by minors.
REDACTED
is gra
ED 
is gra
dults w
CTE
dults w
or dec
DACT
or dec
ed acc
REDA
ed acc
lar t
RE
lar t
COPY 
e clini
COP
e clini
an
C
an
This document
9.1
ment 
9.1
cannot
tee/
ot 
tee/
be pro
anno
be pro
be
y stud
be 
y stud
/I
b
/In
b
n
used
CTIO
d 
CTIO
d
u
d
u
to 
ION
to
ION
support 
s defin
upp
s defin
any marketing 
ces
g
ces
ty
ti
type o
ting
pe o
yp
y
ti
yp
y
tion to 
rket
tion to 
onsor.
mar
onsor.
authorization
nical 
ion 
nical 
nted b
zatio
nted b
with re
oriza
with re
cides 
utho
cides 
ess p
au
ss p
application
at the
on 
at the
de
a
de
and
r w
d
r w
The M
and 
The M
e l
a
e l
any 
which
any
which
extensions or variations 
ve 
a
ve 
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 30 of 72

Male/female subjects from 16 years or older. Subjects under 18 years may only be 
included where legally permitted and ethically accepted.

Subjects with epilepsy who participated in previous BRV studies which allow access to 
the present study.

Subjects from whom the Investigator believes a reasonable benefit from the long-term 
administration of BRV may be expected.

Female subjects without childbearing potential (premenarcheal; 2 years postmenopausal 
bilateral oophorectomy or ovariectomy, bilateral salpingectomy, complete hysterectomy, 
congenital sterility) are eligible. Female subjects with childbearing potential are eligible 
if they use a medically accepted contraceptive method for the duration of the study (Intra 
Uterine Device, diaphragm with spermicide, male or female condom with spermicide; 
oral hormonal contraceptive, non-oral hormonal contraceptive medication, bilateral tubal 
ligation, bilateral tubal implant, monogamous relationship with vasectomized partner). 
Oral or depot contraceptive treatment with at least 30 µg [or 50 µg if associated with 
other antiepileptic drugs known as inducers] ethinylestradiol per intake must be used in 
conjunction with a barrier method. The subject must understand the consequences and 
potential risks of inadequately protected sexual activity, be educated about and understand 
the proper use of contraceptive methods, and undertake to inform the Investigator of any 
potential change in status.  According to the judgment of the Investigator, sexual 
inactivity might be accepted on a case by case basis.

Subject/legally acceptable representative considered as reliable and capable of adhering to 
the protocol (e.g. able to understand and complete diaries and questionnaires), visit 
schedule or medication intake according to the judgment of the Investigator.
9.2
Subject Exclusion Criteria
Subjects must be excluded if they meet any of the following criteria:

Severe medical, neurological and psychiatric disorders or laboratory values which may 
have an impact on the safety of the subject.

Poor compliance with the visit schedule or medication intake in the previous BRV study.

Participation in any clinical study of another investigation drug or device during the 
study.

Pregnant or lactating woman.
If the Investigator has any medically valid reason to doubt the eligibility of a subject, the 
subject should not be included into the study. If, however, the Investigator has any other kind 
of doubts concerning the subject’s eligibility, he/she should consult the UCB Study Physician
(SP) or representative for clarification.
9.3
Subject Withdrawal
Investigators should attempt to obtain information on subjects, in case of withdrawal or 
discontinuation. The Investigator should make every effort, and document his/her effort, to 
REDACTED
the ju
TED 
the ju
by
ACT
by ca
CTE
ca
y
CT
y
ntative
DAC
ntative
and an
RED
and an
co
R
co
COPY 
must
Y
must
l activ
OPY
l activ
unde
CO
unde
This document
subje
ent 
subje
of d
men
of d
(
m
(
cannot 
nan
t
nan
he
ca
he Inv
can
Inv
ec
c
ec
be 
nt or
be
nt or
used
n in a
sed 
n in a
to
ce w
to 
ce w
support
if th
ort 
if th
rologic
ppor
rologic
n the sa
supp
n the sa
it
s
it
any 
they
an
they
marketing
and c
ng 
and c
ording t
eting
ording t
eria
ma
eria
authorization
v
ertake
tion 
ertake
udgme
izati
udgme
se ba
horiz
se ba
e cons
auth
e cons
co
au
co
application
50 µg
tion 
50 µg
iol per
catio
iol per
ndersta
pplic
ndersta
ty
ap
ty, be
app
, be
and 
dica
d
dica
vasec
and
vasec
a
any
with 
ny 
with 
ation
an
ation
extensions
opau
ns 
opau
terect
sion
terect
al are 
tens
al are 
f the 
exte
f the 
e
e
or 
usa
o
usa
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 31 of 72
complete the Early Discontinuation Visit and preferably also the Down-Titration Phone Call 
and the Final Visit. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The Case Report Form (CRF) must document the primary reason for withdrawal 
or discontinuation.
The study medication will be progressively down-titrated. During the down-titration period, 
the dose may be decreased in steps of a maximum of 50 mg/day on a weekly basis. A last 
down-titration step at 20mg/day for 1 week will be included prior to the study -drug free 
period. The down-titration period will be followed by a period free of study drug of a 
minimum of 2 weeks and a maximum of 4 weeks and subsequently, the Final Visit will occur.
9.3.1
Withdrawal Criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care.
Stopping rules and discontinuation criteria for individual subjects may be for example:

Withdrawal for safety reasons by the Investigator: occurrence of status epilepticus, 
appearance of a more severe type of seizure, liver enzymes significant increase, and any 
other significant safety reason.

Subject and/or Investigator does not think that the investigational drug is effective (i.e., 
lack or loss of efficacy).

Lost to follow-up.

Withdrawal of consent for personal reasons; not related to AE or lack/loss of efficacy.

Other reason that has to be specified in the CRF.
Withdrawal criteria for already enrolled subjects who did not complete a C-SSRS assessment 
at screening:

Subject has a lifetime history (prior to study entry or since study start) of suicide attempt 
(including an active attempt, interrupted attempt, or aborted attempt) of the “Already 
Enrolled Subjects” version of the C-SSRS. The Investigator must withdraw the subject 
from the study and immediately refer the subject to a Mental Healthcare Professional.

Subject had active suicidal ideation prior to study entry or since study start as indicated by 
a positive response (‘Yes’) to either Question 4 or Question 5 of the “Already Enrolled 
Subjects” version of the C-SSRS. The Investigator must immediately refer the subject to a 
Mental Healthcare Professional and use clinical judgment as to whether to withdraw the 
subject from the study. 

Subject has active suicidal ideation as indicated by a positive response (‘Yes’) to either 
Question 4 or Question 5 of the “Since Last Visit” version of the C-SSRS.  The subject 
should be referred immediately to a Mental Healthcare Professional and must be 
withdrawn from the study.
REDACTED
estiga
ED 
estiga
izure,
CTE
izure,
not th
RED
not th
COPY 
dividu
COP
dividu
t
C
t
This document 
S
t 
S
ot
cann
bject 
not 
bject 
a posi
cann
a posi
Su
ca
Su
be
S
e
he stu
be 
he stu
used
an act
sed 
an act
Subje
use
Subje
to
fetim
to 
fetim
i
t
i
support 
already
ppor
already
pp
me
s
me
any
spec
any 
spec
marketing 
hink
g
hink
rsonal 
ma
sonal 
i
authorization
ual s
ion 
ual s
tor
zat
tor: o
atio
: o
, liver 
horiz
, liver 
nk th
au
nk th
application 
out prej
atio
out prej
sub
a
sub
and any
nal V
ny 
nal V
extensions
per
ns 
per
A la
ions
A la
drug f
ensi
drug f
drug
exte
drug
e
l V
e
l V
or 
riod
or
riod
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 32 of 72
After decision of subject’s discontinuation, the Investigator will provide the subject with 
information about available alternative treatments.
9.3.2
Subject Replacement Policy
Not applicable.
10
TREATMENT OF SUBJECTS (INVESTIGATIONAL PRODUCT AND 
CONCOMITANT MEDICATIONS)
10.1
Study Investigational Products
10.1.1 Description of all Investigational Products
Active investigational product (tablets containing 10 or 25 mg BRV) will be supplied under 
the responsibility of the Sponsor Clinical Trial Supply Department for all subjects. The 
frequency at which investigational product will be supplied to each individual site will be 
adapted to the recruitment capacity of that site and to the expiry date of the investigational 
product.
10.1.2 Dosing Schedule
Subjects coming from BRV studies have the opportunity to access BRV treatment at a 
flexible dose of up to a maximum of 200 mg/day in b.i.d. administration.  It is recommended 
that the daily dose be divided equally, taken with or without food, and that the first intake will
be in the evening of the day of the dispensation of the study medication.
The individual starting dose of each subject will be the one defined/reached at the end of the 
previous study.  It is recommended that the dosing be done in even increments such as 20 mg, 
30 mg, 40 mg, etc. with the implementation of the IVRS/IWRS.  
At each subject visit, if necessary, the dosage can be adapted:

Up-titration can be made by increments of maximum 50 mg/day on a weekly basis and 
this to a maximum of 200 mg/day.

Dose decreases can be made by steps of maximum 50 mg/day on a weekly basis.  A last 
down-titration step at 20mg/day for 1 week will be included prior to the study-drug free 
period.
At each visit, an IVRS/IWRS will be responsible for issuing subjects kits of study 
medication, as appropriate, according to the visit schedule and according to the supplies 
needed by the subject in terms of number of containers of each size (80 or 200) and of each 
dosage (10 mg or 25 mg tablets) according to the dose prescribed and the possibility to down-
REDACTED
e and
ED 
e and
COPY
r
Y
r
ply
OPY
ply D
PY 
D
be sup
COP
be sup
d
C
d
This document 
d
t
d
not
titrat
not 
titrat
can
his to 
anno
his to 
Dos
ca
Dos
be
bject
be 
bject
tio
b
tio
used
tc. w
ed 
tc. w
t v
u
t v
to
s re
to 
re
wit
to
wit
support 
o
t
o
g dose 
upp
g dose 
recom
su
ecom
any
qual
ny 
qual
f the 
any
f the 
marketing 
have th
rket
have th
of 
ma
of 200
ar
200
all
m
ally
m
y
authorization
pplie
ion 
pplie
to the
zatio
to the
application 
mg 
pli
mg BR
ica
BR
epartm
app
epartm
d t
a
d t
and any extensions 
T AND
ensi
T AND
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 33 of 72
titrate/up-titrate by a maximum of 50 mg/day steps.  Containers of 80 tablets will be 
progressively removed.
In case the subject will not continue with BRV, the Investigator will plan the progressive 
down-titration of the study drug. The down-titration period will be followed by a period free 
of study drug of minimum 2 weeks and a maximum of 4 weeks and subsequently the Final 
Visit will occur.
At the time of study termination by the Sponsor (as defined in Section 8.4), subjects will 
discontinue the study drug following the described down-titration process or will be 
converted without down-titration to commercial BRV, when and where available.  
Alternatively, subjects may transition into another BRV study, or be initiated without 
down-titration in a managed access program, named patient program, compassionate use 
program, or similar type of access program as allowed per country-specific legal and 
regulatory requirements.
10.1.3 Packaging
Oral tablets of 10 mg and 25 mg BRV will be packaged in bottles of 80 and 200 tablets.
Containers of 80 tablets will be progressively removed.  On request via the IVRS/IWRS, the
Investigator will be supplied with a sufficient number of containers. Each container will have 
a unique, pre-printed identification number. 
The Investigator will inform each subject on how to take the drug and that an excess of drug 
is present in the investigational product container.
10.1.4 Labeling
Clinical drug supplies will be labeled in accordance with the current ICH guidelines on GCP 
and Good Manufacturing Practice (GMP) and will include any locally required statements.
The labels and the size of the investigational product package will be adapted to local 
regulatory requirements. The labels will be translated as appropriate.
The label will consist of 2 parts. The first is a tear-off sticker which must be attached to the 
Case Report Form at the time of visit and the second remains fixed to the investigational 
product package. The subject number, subject initials and dispensation date will be added 
manually by the Investigator before dispensing.
10.1.5 Storage Requirements
Investigational product packages should be stored in a secured limited access area and 
maintained at the storage temperature specified on the investigational product package label. 
A recording of this controlled temperature should be done on site. If the storage conditions 
REDACTED
pac
D
pac
y rem
TED 
y rem
cient n
ACTE
cient n
mber.
EDAC
mber.
bj
R
bj
COPY 
ckag
CO
ckag
This 
ent
prod
nt 
prod
docume
man
men
man
cannot
bel w
not 
bel w
e Rep
cann
e Rep
duc
ca
duc
be 
eq
e
eq
used
the si
sed 
the si
quire
use
uire
to support 
will be l
ppo
will be l
ring Pr
sup
ring Pr
any 
keting 
ect on 
keting
ect on 
mar
duct co
arke
duct co
authorization 
ged in
tion
ged in
moved.
rizat
moved.
numbe
thoriz
numbe
application 
y-
on
y-spe
on 
sp
and
t
d
t
m, com
and 
m, com
pec
a
pec
any
aila
ny 
aila
ated 
any
ated 
extensions 
bjects 
ensi
bjects 
will b
exte
will b
abl
e
abl
or 
al
r
al
variations 
ee
a
ee
l
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 34 of 72
are not controlled (with recording), a temperature log should be completed at least once a 
week with the minimal and the maximal temperatures reached in the week preceding the 
record. Any excursion from the allowed temperature range will be communicated to the 
Sponsor or representative.
Storage should be in a pharmacy or in a locked facility. Supplies for this study will be stored 
in such a way that they may not be mixed up with supplies being used for another study. A 
standard storage statement will appear on each investigational product package label of study
medication.
The Investigator or the hospital pharmacist is responsible for the appropriate storage and 
documentation of investigational product package at the site.  The Investigator will instruct 
the subject/legally acceptable representative to store the medication at the storage temperature 
specified on the investigational product package label, in a secure place out of the reach of 
children.
10.1.6 Monitoring of Subject Compliance
At each visit after drug is dispensed, subjects must return all unused medication and the 
original investigational product package (even if empty). Drug reconciliation must be done in 
the subject’s presence in order to obtain explanations regarding discrepancies in compliance 
with the dosing regimen.
The number of tablets as well as explanations of non-compliance must all be recorded on the 
CRF.
Compliance with study medication is defined as investigational product consumption by the 
subject within 80% - 120% of the prescribed dosage.
10.1.7 Investigational Products Accountability
The Sponsor or its representatives will supply a Drug Accountability Form to be kept up-to-
date by recording all study drug received during the course of the study and study drug 
released for subject use. Details of any drug lost (due to breakage or wastage), not used, 
disposed of at the study site or returned must also be recorded.  All supplies and pharmacy 
documentation must be made available throughout the study for the Sponsor or designee to 
review.
The Drug Accountability Form should include the following:

Number of tablets dispensed to and return by each subject, with the subject’s number and 
carton or bottle number.

Initials of the person who actually dispensed and/or received the return tablets.

Dates of the above.
REDACTED
mus
ED 
mus
ven if
CTE
ven if
expla
DACT
expla
COPY 
st
C
st
This 
nt
c
t
c
documen
revie
ent 
revie
no
d for 
ot 
d for 
can
osed o
anno
osed o
ume
ca
ume
be
ordi
be 
ordi
r su
b
r su
used 
or its r
used
or its r
in
u
in
to
onal
to 
onal
support
ic
t
ic
% of t
port 
% of t
al Pr
su
al Pr
any 
ation
any
ation
marketing 
lanatio
rket
lanatio
authorization 
return
zatio
return
f empt
oriza
f empt
anatio
utho
anatio
application
e plac
on 
e pla
and
st
d
st
at the
and 
at the
ace
a
ace
any
te s
ny 
te s
igato
any
igato
extensions 
dy
ns
dy.
s
.
bel of 
sions
bel of 
s
sto
e
sto
or 
or
r
or
A
or
A
variations 
red
va
red
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 35 of 72

Explanations for non-compliance.
Periodically and after completion of the study, all used (including empty cartons and bottles) 
and unused investigational product package must be reconciled and returned (preferably in 
their original package) to the Sponsor or designee according to a procedure to be defined at 
the time. Clinical drug supplies designated for the study cannot be used for any other purpose 
than that described in this protocol.
10.2
Concomitant Treatments and Rescue Medications
For any treatment other than BRV, an accurate record must be kept in the clinic chart (source 
documentation) and the Case Report Form. This record should include the brand name of the 
drug, the dose, frequency, route, the indication for use and the date(s) of administration.
10.2.1 Permitted Concomitant Treatments (Medications and Therapies)
Investigator may adapt the AED drug/dosage for safety or efficacy reasons.  Benzodiazepines 
(BZD) taken more than once a week (for any indication) will be considered as a concomitant 
AED. 
10.2.2 Prohibited Concomitant Treatments (Medications and Therapies)
Vigabatrin
11
STUDY PROCEDURES
11.1
Description of Procedures
11.1.1 Informed Consent
Prior to any study activities, subjects will be asked to read and sign an informed consent form 
that has been approved by an IEC/IRB and which complies with regulatory requirements. 
Subjects will be given adequate time to consider any information concerning the study, given 
to them by the Investigator or designee.  As part of the informed consent procedure, subjects 
will be given the opportunity to ask the Investigator any questions regarding potential risks 
and benefits of participation in the study.
Where legally acceptable, a Partner Pregnancy Consent Form will be issued in case the 
partner of a male subject becomes pregnant (Section 12.1.6).
REDACTED 
ments 
DAC
ments 
COPY
afet
OPY
afety o
PY 
y o
icatio
COP
icatio
This document 
nd 
t
nd 
W
me
W
cannot
by
not
by t
ot 
t
y
ot
y
be giv
anno
be giv
ben
ca
ben
be
ill b
be 
ill b
th
b
th
ed
dy
ed
dy
u
ac
ed 
ac
appro
use
appro
u
to 
cti
to
cti
support 
oce
rt
oce
sent
supp
sent
any 
edur
any
edur
marketing 
S
m
S
authorization
on) w
ion 
on) w
(Med
utho
(Med
application 
d Thera
catio
d Thera
r effic
app
r effic
wil
a
il
and
t
d
t
s) of a
and 
s) of a
any
clini
ny 
clini
he 
an
he br
ny
br
extensions 
nic
e
nic
or 
rpo
or
rpo
variations 
pose
va
pose
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 36 of 72
11.1.2 Subject Study Card
The Sponsor will provide to each Investigator an appropriate quantity of subject study cards 
that contains the Investigator’s contact information in case of emergency. These subject 
cards will be in the language of the subject. The Investigator will fill in each card with 
his/her contact details (name and telephone number) and the subject’s identifier. This card 
will be distributed to the subject at the Entry Visit. The Investigator will instruct the subject 
to keep the card with them at all times.
11.1.3 Demography
At the first visit, date of birth, gender and racial group will be recorded.
11.1.4 Childbearing Potential and Birth Control
At the first visit, information on childbearing potential and contraceptive method used by 
female subjects will be collected. During the course of the study, the Investigator should 
make sure that birth control remains optimal should the subject’s status change. A pregnancy 
test will be performed as specified in the Study Flowchart (see Table 5:1).
11.1.5 General Medical and Procedure History
The General Medical and Procedure History will be transferred from the database of the 
previous study in which the subject was participating.
11.1.6 Epilepsy History
The history of epilepsy reported at the first visit of the previous study in which the subject 
was enrolled will be considered as the history of epilepsy for the present study and will be 
directly electronically transferred from this study.
11.1.7 Antiepileptic Medication History
The AED medication history will be transferred from the database of the previous study in 
which the subject was participating. The AED being used concurrently, at the current dose, 
will be recorded on the concomitant AED medication page of the CRF.
11.1.8 Vital Signs
At every visit, after 5 minutes supine or sitting, pulse rate and blood pressure will be obtained 
followed by a standing pulse rate and blood pressure. At the Entry Visit, vital signs will be 
obtained electronically from the last Evaluation Visit of the previous study and should not be 
recorded in the CRF.
REDACTED 
dy
ED
dy Fl
ED
Fl
e Hist
DAC
e Hist
His
RE
His
COPY
l a
Y
l a
e of 
OPY
e of th
Y 
th
uld 
CO
uld th
OP
th
ow
C
ow
This document 
ill
t
ill
11
me
11
no
D m
ot 
D m
can
h the 
anno
h the 
l be r
ca
 be r
be 
me
b
me
used 
pilepti
use
pilepti
to
l
o
ly t
to 
y t
support
eported
port 
eporte
onsider
upp
onsider
y tran
su
tran
any 
eting 
story
ting
story
mark
w
g
w
y
g
y
was par
rket
was par
authorization
e 
o
e su
on 
su
wchar
zatio
wchar
tory
utho
tory
application 
contrac
plica
contrac
he 
a
he stud
app
stud
bj
a
bj
and 
d any extensions
subj
ns 
subj
or 
d
r
d
bjec
or
bjec
variations 
d
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 37 of 72
11.1.9 Weight and Height
Body weight (subject wearing light clothing without shoes and rounded to the nearest 
kilogram) will be obtained at the following visits: Entry Visit, each Full Evaluation Visit, 
each Yearly Evaluation Visit, Early Discontinuation Visit, and at the Final Visit. Height will 
be obtained at the Entry Visit. For subjects that are still potentially growing, height will also 
be measured at each Yearly Evaluation Visit and the Final Visit.
11.1.10 Physical Examination
A standard physical examination will be performed at the following visits: every Full 
Evaluation Visit, each Yearly Evaluation Visit, Early Discontinuation Visit and at the Final 
Visit. This examination may include investigation of skin, eyes, ear, nose, throat, 
cardiovascular system, respiratory system, gastro-intestinal system, musculoskeletal system 
and optionally genitourinary system. At the Entry Visit, the physical examination will be 
obtained electronically from the last Evaluation Visit of the previous study and should not be 
recorded in the CRF.
11.1.11 Neurological Examination
A standard neurological examination will be performed at the following visits: every Full 
Evaluation Visit, each Yearly Evaluation Visit, Early Discontinuation Visit and at the Final 
Visit. This examination will consist of a brief review of cortical functions, cranial nerves, 
motor function, reflex function, sensory function, gait and stance. Psychiatric and mental 
status will be reported by recording the presence or absence of psychiatric symptoms, mental 
impairments and behavioral symptoms. At the Entry Visit, the neurological examination will 
be obtained electronically from the last Evaluation Visit of the previous study and should not 
be recorded in the CRF.
11.1.12 ECG
Once the subject has signed the updated Informed Consent, the number of standard 12-lead 
ECGs will be reduced to once per year at the following visits: Yearly Evaluation Visit, Early 
Discontinuation Visit, and Final Visit (in case the FV follows an EDV and the EDV ECG is 
normal, no additional ECG has to be performed at FV). At the Entry Visit, the ECG will be 
obtained electronically from the last Evaluation Visit of the previous study and should not be 
recorded in the CRF.  The Investigator will determine whether the results of the ECG are 
normal or abnormal and assess the clinical significance of any abnormalities.  The original 
ECG tracing will be signed or initialed and dated by the Investigator and retained as part of 
the source data.
REDACTED 
will b
REDA
will b
atio
RE
atio
COPY
it
Y
it
sit of t
OPY 
sit of t
This document
orm
t
orm
obtai
ent 
obtai
re
me
re
anno
will b
ot 
will b
ontinu
nno
ontinu
c
mal,
ca
mal,
be
ubje
be 
ubje
be
b
be
used 
ct
u
ct
to support
sy
t
sy
y
p
y from
port 
from
y
p
y
F.
u
F.
any
ding
ny 
ding
y
a
ympt
any
mpt
ym
y
a
ym
y
marketing 
be
g
be
on Visi
ting
on Visi
of a br
ket
of a br
ensory
mar
ensory
g th
m
g th
authorization 
e per
au
e per
application
ear, n
on 
ear, n
stem, m
atio
stem, m
e phy
plica
e physi
a
si
he pre
app
he pre
and
sit
d
sit
on Vis
and 
n Vis
no
a
no
any 
s:
a
s: ev
n
ev
extensions 
ill 
s
ill 
or 
wi
or
wi
als
or
als
variations 
will 
va
will 
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 38 of 72
11.1.13 Daily Record Card (DRC)
At the Entry Visit, every Full Evaluation Visit, every Minimal Evaluation Visit, Yearly 
Evaluation Visit, and the Early Discontinuation Visit, the subject will receive a Daily Record 
Card (DRC) and will be asked to come back at the next visit with the completed DRC.
The following information will be recorded on the DRC:

Date and the number (where possible) of epileptic seizures

Type of seizure (according to individual description of epileptic seizures)

Occurrence of seizure clusters

All unusual events concerning the subject’s health

Changes in concomitant medication (dosage and/or product)

Changes in investigational product (dosage)
The written information will be discussed with the subject at each visit in order to ensure 
completeness and accuracy.  As a result of the discussion, the Investigator will assess the 
epileptic seizures according to the ILAE codes and record the seizure types and frequency on 
the CRF; he/she will also confirm the presence of adverse events (if applicable).  The 
concomitant medication changes and adverse events will be reported by the Investigator on 
the specific pages of the CRF.
The DRC will be considered part of the CRF as well as source documentation.  The subject 
should be educated to complete the DRC on a regular basis (each time that a seizure, an 
undesirable event, a modification of medication or investigational product, or a medical visit 
occurs).
11.1.14 Laboratory Assessments
At the following visits, Full Evaluation Visit, Yearly Evaluation Visit, Early Discontinuation 
Visit, and Final Visit, laboratory assessments will be conducted using standard methods at a 
central laboratory. At the Entry Visit, data will be transferred electronically from the last 
Evaluation Visit of the previous study and should not be recorded on the CRF.  The central 
laboratory will provide the Investigator with dedicated, standardized sampling equipment 
(labels, needles, tubes), and a study-specific laboratory manual, which will explain how to 
use the equipment and how to ship the samples back to the central laboratory. 
Results for hematology, chemistry, urinalysis and pregnancy tests will be provided by fax to 
the Investigator within 72 hours after sample receipt. 
The total blood volume drawn for the clinical laboratory assessments will be a maximum of 
20 ml/sampling. The subject should preferably be fasting. Study medication intake must not 
be delayed.
REDACTED
o
D
o
e even
TED 
e even
the C
RED
the C
DR
R
DR
COPY
sion
PY 
sion
d recor
OPY
d recor
f adv
CO
f adv
This document 
Res
men
Res
th
m
th
cannot
y
t
y
t
y
t
y
, need
not 
, need
the eq
cann
the eq
be
Vi
e
will 
be 
will 
sed
ory
sed
ory
u
.
ed
. A
d 
A
sit o
use
sit o
to
sit,
to
sit, l
o 
l
A
t
A
support
men
ort 
men
s
s
s,
s
, Full
supp
Full
lab
s
lab
any 
nts
a
nts
marketing
CRF 
ng 
CRF 
RC on 
keting
RC on 
f medic
arke
f medic
authorization
ord
n
o d
verse 
tion 
verse 
nts wi
izati
nts wi
F as
a
F as
application 
each v
icatio
each v
the Inv
pplic
the Inv
d the 
app
d the 
and any extensions 
es)
ten
es)
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 39 of 72
The following laboratory assessments will be conducted:

Blood chemistry: glucose, urea, creatinine, sodium, potassium, calcium, phosphorus 
(inorganic), total protein, albumin, total bilirubin, alkaline phosphatase (ALP), aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase (ASAT/SGOT), alanine 
aminotransferase/serum glutamic pyruvic transaminase (ALAT/SGPT), gamma-
glutamyltranspeptidase (GGT), and uric acid.

The creatinine clearance (Cr Cl) will be calculated by the Cockroft’s formula (only at the 
Entry Visit): 

male: Cr Cl ml/min = [(140-age) x body weight] / (72 x serum creatinine 
(mg/dl)].

female: Cr Cl ml/min = [(140-age) x body weight] / [72 x serum creatinine 
(mg/dl)] x 0.85.

Hematology: white blood cells (WBC), red blood cells (RBC), hemoglobin, hematocrit, 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), platelet count, lymphocytes (number, 
%), monocytes (number, %), neutrophils (number, %), eosinophils (number, %), 
basophils (number, %).

Urinalysis: specific gravity, pH, glucose, bilirubin, ketones, occult blood, protein, 
nitrites, leukocytes. If the test for protein, blood or leukocytes shows a trace or is 
positive, sediment and microscopic analyses (erythrocyte cast, leukocyte casts, 
hemoglobin casts, uric acid crystals, bihydrate calcium oxalate crystals, monohydrate 
calcium oxalate crystals, triple phosphate crystals and bacteria) will be conducted.

Where applicable (women of childbearing potential), a urine pregnancy test will be 
conducted. 
Plasma samples to analyze BRV and concomitant AED plasma concentrations will no longer 
be obtained.
11.1.15 Adverse Events (AEs)
At the Entry Visit, the Investigator will record any adverse event that was still ongoing at the 
end of the previous study. From the entry Visit onwards, adverse events will be assessed at 
each visit and recorded in the CRF and in the source documents. The study participant will 
be given the opportunity to report AEs spontaneously. A general prompt will also be given to 
detect AEs, e.g., “Did you notice anything unusual about your health (since your last visit)?” 
In addition, the Investigator should review any self-assessment procedures (e.g. daily record 
cards) used in the study.
11.1.16 Assessment of Suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS.  This scale will be 
used to assess suicidal ideation and behavior that may occur during the study.  The C-SSRS 
will be completed according to the tabular schedule of assessments (Section 5.1).
ACTED
ili
D
ili
n, bloo
TED 
n, bloo
nal
AC
nalys
CT
yse
T
e
RED
s, bihy
EDAC
s, bihy
hosph
RED
hosph
d
R
d
COPY 
r, %
Y
r, %
irubi
CO
irubi
This document
n ad
nt 
n ad
card
men
card
cannot
a
t
a
en the
not 
en the
ect AE
cann
ect AE
dd
ca
dd
be
rev
e
rev
and r
be 
and r
sed
isit, th
sed 
isit, th
u
viou
use
viou
to support 
nts (AE
sup
nts (AE
any
V
an
V an
ny 
an
marketing
hate 
ng 
hate 
dbearin
keting
dbearin
d
thorization
in, ket
tion 
in, ket
od or 
izati
od or 
s 
h
s (ery
horiz
(ery
aut
y
a
ydrate
auth
drate
e c
a
e c
application
lobin 
tion 
lobin 
count, 
icatio
count, 
eosino
pplic
eosino
and 
hemo
and
hemo
(
a
(
any 
um c
ny 
um c
extensions 
ly
ns
ly at
s
at
y
s
y
atinin
tens
atinin
e
or 
at th
o
at th
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 40 of 72
11.1.17 Medical Procedures
From the Entry Visit onwards, collection of data on medical procedures (surgery, therapeutic 
and/or diagnostic, hospitalizations) undertaken during the study will be obtained. ECGs 
specific to this study will not be recorded on the Medical Procedures page of the CRF but in 
the modules specifically designed for this purpose.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or 
t in
or
t in
variations 
in
va
in
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 41 of 72
11.1.18 Non-Antiepileptic and Antiepileptic Concomitant Medications
At the Entry Visit, the Investigator will record all Non-Antiepileptic and Antiepileptic 
Concomitant Medications that were still ongoing at the end of the previous study. All 
medications (including over-the-counter preparations) taken during the course of the study
must be documented in the CRF (brand name, indication, dosage, and the dates of start and 
discontinuation).
At each visit, a complete listing of all medications currently being taken will be obtained. 
Any changes, additions or deletions in the administration of non-antiepileptic concomitant 
medications must be recorded on the Non-Antiepileptic Concomitant Medications page of the 
CRF. In case of intake of prohibited concomitant medication (see Section 10.2.2) during the 
study period, the Investigator will contact the monitor immediately.
Changes, additions or deletions in the administration of antiepileptic concomitant medications 
must be recorded on the Antiepileptic Concomitant Medications page of the CRF.
11.1.19 Patient Reported Outcomes
A Patient Reported Outcomes (PRO) booklet per visit will be created for the FEV, YEV as 
well as for EDV. The assessment of the Patient Reported Outcomes will be limited to the 
first 2 years after study entry, which includes the YEV of Year 3.  These booklets will 
include, in order of appearance: The Patient Weighted Quality of Life in Epilepsy Inventory -
31 item form (QOLIE-31-P - Version 2), the Hospital Anxiety and Depression Scale 
(HADS), and the EQ-5D self report questionnaire. The PRO booklet is to be provided to 
subjects that are not mentally impaired, at the very beginning of the study visit. The subject 
will be asked to complete the questionnaires on his/her own. Once completed, the subject 
will hand back the booklet to the Investigator who will check that all questions have been 
answered.
Subjects coming from N01193 will not have to complete the PRO booklet. All other subjects 
that are not mentally impaired will complete the PRO booklet at FEV, YEV and/or EDV for 
the first 2 years.
The PRO booklets will be considered as part of the CRF as well as source documentation.
11.1.20 Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)
QOLIE-31-P (Cramer and Van Hammée, 2003) is an adaptation of the original QOLIE-31 
instrument (Cramer et al, 1998) that includes 7 subscales (seizure worry, overall quality of 
life, emotional well-being, energy-fatigue, cognitive functioning, medication effects, social 
function) and the health status item. Subscale scores as well as Total score range from 0 to 
REDACTED 
ooklet 
DACT
ooklet 
the Pa
REDA
the Pa
inc
RE
inc
COPY
of 
Y
of 
Medi
OPY 
Medi
This document 
he
t
he
11
me
11
annot
2
o
2
c
ye
ot 
ye
e PR
ca
 PR
be
t me
be 
t me
e
b
ea
b
a
used 
ing fro
used
ng fro
nt
u
nt
to support
y
t
y
t
y
t
y
e the q
port 
e the q
klet to
upp
klet to
any
port
ny 
port
impa
any
impa
marketing 
ati
g
ati
cludes 
ting
cludes 
e Patien
rket
e Patien
sion 2)
mar
sion 2)
rt q
m
rt q
authorization 
per v
utho
per v
ient 
au
ient 
application 
ly
on
ly.
on
.
iepilept
plica
iepilept
cation
app
cation
and
Me
d
Me
ection
and 
ection
any
tic c
ny 
tic c
dicat
any
dicat
extensions
rt an
ns 
rt an
be ob
exte
be ob
c co
e
c co
or 
dy
or
dy
and
or
and
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 42 of 72
100 with higher scores indicating better health related quality of life. In addition to the 31 
items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to grade his or 
her overall "distress" related to the topic of each subscale.  The QOLIE-31-P also contains an 
item asking about the relative importance of each subscale topic. The subjects will complete 
the QOLIE-31-P at every Full Evaluation Visit and Yearly Evaluation Visit for the first 
2 years, and at the Early Discontinuation Visit if the Early Discontinuation Visit occurs 
within the first 2 years.
11.1.21 Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) (Herrmann, 1997) will be used to 
evaluate anxiety and depression/depressed feelings. The HADS was developed as a self 
administered scale to assess the presence and severity of both anxiety and depression 
simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging 
from 0 to 3. A score per dimension (anxiety, depression) will be calculated as recommended 
by the authors with each score ranging from 0 to 21 and higher scores indicating higher 
depression/anxiety. The subjects will complete the HADS at every Full Evaluation Visit and 
Yearly Evaluation Visit for the first 2 years, and at the Early Discontinuation Visit if the 
Early Discontinuation Visit occurs within the first 2 years.
11.1.22 EQ-5D Questionnaire
The EQ-5D (EuroQol Group, 2000) is a self-administered questionnaire designed to measure 
health status. EQ-5D defines health in terms of 5 dimensions (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression). Each dimension is divided into 3 levels:

no problem = 1.

some or moderate problems = 2.

extreme problems = 3.
EQ-5D also captures a self-rating of health status on a 20 cm vertical visual analogue scale, 
anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) 
at the bottom.
The EQ-5D questionnaire will be assessed at every Full Evaluation Visit and Yearly 
Evaluation Visit for the first 2 years, or at the Early Discontinuation Visit if the Early 
Discontinuation Visit occurs within the first 2 years.
11.1.23 Hospital Stay
From Entry Visit onwards, the collection of data on hospital stay will be assessed in the CRF. 
It includes the reason of hospitalization, the admission wards, transfer and length of stay.  
Hospital stays will be assessed at every Full Evaluation Visit, Minimal Evaluation Visit, and 
REDACTED
first
ED 
first
is a
RE
is a
COPY
nd
Y
nd
HAD
OPY 
HAD
at the
COP
at the
t 2
C
t 2
This document 
isc
t
isc
1
m
1
not
Q
n
Q-5D 
not 
5D 
can
uation
ann
uation
con
ca
con
be 
b
used
 (bes
ed 
 (bes
to
es a 
to 
es a 
st
t
st
support 
em
rt
em
3
p
3.
p
.
a se
s
a se
any 
ms = 
an
ms = 
eting 
self
ting
self-
g
-f-f
g
f-f a
g
a
mark
in term
rket
in term
xiety
mar
xiety/d
ar
/d
y/y
ar
y/y
authorization
e Ear
ion 
e Ear
2
z
2 ye
zatio
yea
tio
a
application
nt sev
on 
nt se
be calc
atio
be calc
gher sco
plica
gher sco
S at ev
app
S at ev
rl
a
rly
a
y
and
ev
d
ev
y
a
y and
and 
and
y
a
y
ev
a
ev
any 
l b
y
l b
elope
any
elope
extensions 
be
e
be
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 43 of 72
Yearly Evaluation Visit, for the first 2 years, and at the Early Discontinuation Visit and the 
Final Visit if these visits occur within the first 2 years.
11.1.24 Healthcare Provider Consultation not Foreseen by Protocol
From Entry Visit onwards, healthcare provider consultation not foreseen by protocol will be 
assessed and recorded in the CRF. It will include the type of provider [general practitioner 
(GP), specialist physician, nurse], site of care (office-private, office-hospital, home, 
emergency room) and the reason leading to the consultation.  Healthcare provider 
consultations not foreseen by the protocol will be assessed at every Full Evaluation Visit, 
Minimal Evaluation Visit, and Yearly Evaluation Visit for the first 2 years, and at the Early 
Discontinuation Visit and the Final Visit if these visits occur within the first 2 years.
11.1.25 Socio-professional Data
Socio-professional data will be collected at the Yearly Evaluation Visit for the first 2 years 
and/or at the Early Discontinuation Visit if the Early Discontinuation Visit occurs within the 
first 2 years in the CRF for subjects coming from N01252, N01253 and N01254 only. It
collects information such as education level, housing status, employment status, need for 
caregiver and driving license.
11.1.26 End of Study
The end of the subject’s participation in the study will be confirmed on the subject’s status 
evaluation section of the CRF.  All data about the subject’s status (study completion or reason 
for early study termination) will be recorded. It will be specified:

Whether the subject completed (participated until the study was stopped) or prematurely 
discontinued the study.
A subject will be considered lost to follow-up following 2 unsuccessful documented attempts 
to contact the subject (e.g. by telephone).
If a subject will not continue with the study drug, the Investigator will first schedule an Early 
Discontinuation Visit which will be followed by a progressive down-titration of the study
drug. The dose decrease can be made by steps of a maximum of 50 mg/day on a weekly 
basis. A last down-titration step at 20 mg/day for 1 week will be included prior to the study-
drug free period.  At the end of the down-titration period, a Down-Titration Phone Call will 
occur for subjects having down-titrated from doses higher than 20 mg/day. The Down-
Titration Period will be followed by a period free of study drug at the minimum of 2 weeks 
and a maximum of 4 weeks and subsequently the Final Visit will occur. 
When the time point is reached at which the study will be terminated by the sponsor (as 
defined in Section 8.4), subjects will discontinue the study drug, following the above 
REDACTED
hous
ED 
hous
COPY
E
Y
E
y
OP
y Dis
OPY 
Dis
m N01
COP
m N01
in
C
in
This 
nt 
si
t
si
documen
drug
ment
drug
oc
me
oc
cannot
tinua
not 
tinua
a
The
anno
The
is.
ca
is. A
a
A
be
t wil
be 
t wil
ati
b
ati
used
bjec
ed 
bjec
l
u
l
to
onsi
to 
onsi
ct
to
ct
support 
mpl
rt
mpl
y
p
y.
p
.
sider
su
sider
any
l be 
ny 
l be 
leted
any
leted
arketing 
n in
rke
n in the
et
the
m
ll data 
mar
ll data 
e re
m
e re
authorization
252,
on 
252,
ng stat
zatio
ng stat
application 
uation
plica
uation
continu
app
continu
N
a
N
and 
f
d
f
any
, an
ny 
, an
first 2
any
first 2
extensions
tion
ns 
tion
e,
si
e,
er
en
er
uation
exte
uation
nd
e
nd
or 
be
or
be
ner
or
ner
variations 
be 
va
be 
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 44 of 72
described down-titration process or will be converted without down-titration to commercial 
BRV, when and where available. Alternatively, subjects may transition to another BRV study 
or be initiated without down-titration in a managed access program, named patient program, 
compassionate use program, or similar type of access program as allowed per 
country-specific legal and regulatory requirements
11.2
Description Visit by Visit
The Entry Visit will be performed on the same day as the last visit of the previous study in 
which the subject was enrolled.  Should an interval become necessary between the last visit of 
the previous study and the entry visit in the present study, the Sponsor’s Study Physician or 
representative should be contacted for agreement. The Adverse Events, Medical Procedures, 
Non-Antiepileptic and Antiepileptic Concomitant Medication belonging to the interim period 
will be reported in the CRF, on specific pages.
Each visit will be planned within a “window” of ± 7 days from the previous visit.
At any time, the subject may have an additional study visit/phone call if the Investigator of 
the subject deems it necessary. All information, including the reason for the visit/phone call, 
any information on adverse events, etc., should be collected in the source documents and 
recorded in the appropriate section of the CRF.
11.2.1 Entry Visit

Signing and dating of written informed consent.

Dispensation of “clinical study subject card” (participation in the study).

Verification of the Inclusion/exclusion criteria.

Demography data: date of birth, gender and racial group.

Childbearing potential.

Medical and procedure history.

Epilepsy history.

AED history.

Vital signs including blood pressure and pulse rate.

Body weight and height.

Physical and neurological examination.

ECG.

Dispensation of subject DRC and instruction on proper completion.

Recording of seizures.

Concomitant medications (AED and Non-AED) documentation.

Laboratory assessment including safety (hematology, blood chemistry, and urinalysis), 
pregnancy test (if applicable).

Recording of Adverse Events.
REDACTED
on, in
ED 
on, in
ould b
CTE
ould b
he CRF
DACT
he CRF
COPY 
ay
Y
ay
study
COP
study
nc
C
nc
This document

E
t 
E

me

ot 
sig
t
sig
canno
d
n
dy w
nnot
y w
Phy
can
Phys
n
s
EC
c
EC
be 
sto
e
sto
igns
be
igns
used 
d
story
sed
story
ory
us
ory
to
oced
to 
oced
support 
sio
rt
sio
date of 
ppor
date of 
ntial.
supp
ntial.
du
s
du
any 
udy
ny
udy
on
an
on/e
an
/e
marketing 
inform
mar
inform
su
m
su
authorization
visit
ion 
visit
cludin
zatio
cludin
be col
oriza
be col
F.
ut
F.
application 
rom the
plica
rom the
t/p
a
t/p
and
s, M
d
s, M
ging t
and 
ging t
any
udy
ny 
udy
Medi
any
Medi
extensions 
us stu
ensi
us stu
n the
exte
n the
y
e
y P
e
P
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 45 of 72

Medical procedures.

Dispensation of study medication (only dispensed once all inclusion/exclusion criteria 
have been met).

Appointment for the next visit according to the schedule described in Section 5.2.
The following data will be transferred from the database of the baseline visit of the previous 
study and should not be recorded in the CRF:

General medical and procedure history.

AED history.

Epilepsy history.
The following data will be transferred from the database of the last evaluation visit of the 
previous study and should not be recorded in the CRF/DRC:

Vital signs including blood pressure and pulse rate.

Physical examination.

Neurological examination.

ECG.

Laboratory assessment including safety (hematology, blood chemistry, and urinalysis).

Pregnancy test (if applicable).

Recording of seizures.
11.2.2 Full Evaluation Visit

Vital signs including blood pressure and pulse rate.

Body weight.

Physical and neurological examination.

Retrieval of previous subject DRC.

Recording of seizures.

Laboratory assessment including safety (hematology, blood chemistry, and urinalysis), 
urine pregnancy test (if applicable).

Recording of Adverse Events.

Assessment of suicidality (C-SSRS).

Medical procedures.

Concomitant medications (AED and Non-AED) documentation.

Drug return/accountability including study medication intake and compliance check.

Dispensation of new DRC.

Dispensation of study medication.

Appointment for the next visit according to the schedule described in Section 5.2.
The following assessments will be performed during the first 2 years which includes the YEV 
in Year 3.
REDACTED 
ema
D
ema
COPY 
mato
CO
mato
This document
D
t 
D

me

cannot
edical
not 
edical
Conco
cann
Conco
Dr
c
Dr
be
g
men
be 
men
used
ancy
ed
ancy
d 
y
d
y
g of A
use
of A
to
essm
to 
essm
te
t
te
support 
al 
t
al 
subjec
port
subje
ures.
supp
ures.
men
s
men
any 
exam
any
exam
marketing 
essure 
mark
essure 
authorization 
ology, 
ation
ology, 
application and 
alua
d
alua
any 
atio
an
atio
extensions or
ous
or 
ous
variations 
us
va
us
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 46 of 72

QOLIE-31-P questionnaire (except if subject mentally impaired and except for all 
subjects coming from N01193).  The questionnaire should be filled in at the beginning of 
the Visit.

HADS questionnaire (except if subject mentally impaired and except for all subjects 
coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, 
after the QOLIE-31-P.

Healthcare provider consultation not foreseen by protocol

Recording of workdays and schooldays lost and days subject received help from a 
caregiver (paid or not) at home.

Hospital stay.

EQ-5D questionnaire (except if subject mentally impaired and except for all subjects 
coming from N01193).
11.2.3 Minimal Evaluation Visit

Vital signs including blood pressure and pulse rate.

Retrieval of previous subject DRC.

Recording of seizures.

Recording of workdays and schooldays lost and days subject received help from a 
caregiver (paid or not) at home during the first 2 years.

Hospital stay during the first 2 years.

Healthcare provider consultation not foreseen by protocol during the first 2 years.

Recording of Adverse Events.

Assessment of suicidality (C-SSRS).

Medical procedures.

Concomitant medications (AED and Non-AED) documentation.

Drug return/accountability including study medication intake and compliance check.

Dispensation of new DRC.

Dispensation of study medication.

Appointment for the next visit according to the schedule described in Section 5.2.
11.2.4 Yearly Evaluation Visit (replaces the first FEV of each year)

Vital signs including blood pressure and pulse rate.

Body weight and height (only for those subjects still potentially growing).

Physical and neurological examination.

ECG.

Retrieval of previous subject DRC.

Recording of seizures.
REDACTED 
ay
A
ays los
ACT
s los
ring th
EDA
ring th
e
R
ears
RE
ars
COPY 
rate.
COPY
rate.
This document
V
nt 
V

me

cannot
Year
not 
Year
Vit
ca
Vit
be 
l
b
l
used 
n of 
ed
n of 
ent f
use
ent f
to
f new
to 
f new
st
t
st
support 
tions (A
port
tions (
ntabili
supp
ntabili
ew D
su
ew D
any 
n
-
y
-SS
ny 
SS
marketing 
not 
ket
not f
etin
for
ti
or
fo
f
ti
fo
f
SSR
m
SSR
authorization 
st and 
thor
st and 
he firs
auth
he firs
application and
cept 
nd 
cept 
any 
t for
a
t for
extensions 
from 
tens
from 
or
Vis
or 
Vis
variations 
isit
va
isit
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 47 of 72

Laboratory assessment including safety (hematology, blood chemistry, and urinalysis), 
urine pregnancy test (if applicable).

Recording of Adverse Events.

Assessment of suicidality (C-SSRS).

Medical procedures.

Concomitant medications (AED and Non-AED) documentation.

Drug return/accountability including study medication intake and compliance check.

Dispensation of new DRC.

Dispensation of study medication.

Appointment for the next visit according to the schedule described in Section 5.2.
The following assessments will be performed during the first 2 years which includes the YEV 
in Year 3.

QOLIE-31-P questionnaire (except if subject mentally impaired and except for all 
subjects coming from N01193).  The questionnaire should be filled in at the beginning of 
the Visit.

HADS questionnaire (except if subject mentally impaired and except for all subjects 
coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, 
after the QOLIE-31-P.

Healthcare provider consultation not foreseen by protocol

Recording of workdays and school days lost and days subject received help from a 
caregiver (paid or not) at home.

Hospital stay.

EQ-5D questionnaire (except if subject mentally impaired and except for all subjects 
coming from N01193).

Socio-professional data.
11.2.5 Early Discontinuation Visit

Vital signs including blood pressure and pulse rate.

Body weight.

Physical and neurological examination.

ECG.

Retrieval of previous subject DRC.

Recording of seizures.

Laboratory assessment including safety (hematology, blood chemistry, and urinalysis), 
urine pregnancy test (if applicable).

Recording of Adverse Events.

Assessment of suicidality (C-SSRS).

Medical procedures.

Concomitant medications (AED and Non-AED) documentation.
REDACTED 
sho
D
sho
forese
ACT
forese
ol day
REDA
ol day
A
COPY 
ll
CO
lly i
COP
y im
OP
m
houl
CO
houl
This document
R
t 
R

me

cannot 
G.
no
G.
Retrie
cann
Retrie
Re
ca
Re
be
a
b
al an
be 
l an
used
nclu
ed 
nclu
ght.
use
ght.
d
u
d
to 
udi
to
udi
support 
inuatio
supp
inuatio
any marketing 
if subje
mark
if subje
authorization
mpai
on 
mpai
ld be f
ation
ld be f
een b
thor
een b
r
lost 
aut
lost 
application 
aired an
ation
aired an
ld be fi
licat
ld be fi
aired
ap
aired
and
whic
nd 
whic
any 
ch
a
ch
extensions 
eck.
ns
eck.
ction
ext
ction
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 48 of 72

Drug return/accountability including study medication intake and compliance check.

Dispensation of new DRC.

Dispensation of study medication with down-titration dosing schedule.

Appointment for the next visit according to the schedule described in Section 5.2.
Down-titration may not be applicable to subjects who may transition to another BRV study or 
may be initiated in a managed access program or similar type of program.   
The following assessments will be performed only if the EDV occurs within the first 2 years.

QOLIE-31-P questionnaire (except if subject mentally impaired and except for all 
subjects coming from N01193).  The questionnaire should be filled in at the beginning of 
the Visit.

HADS questionnaire (except if subject mentally impaired and except for all subjects 
coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, 
after the QOLIE-31-P.

Healthcare provider consultation not foreseen by protocol

Recording of workdays and schooldays lost and days subject received help from a 
caregiver (paid or not) at home.

Hospital stay.

EQ-5D questionnaire (except if subject mentally impaired and except for all subjects 
coming from N01193).

Socio-professional data.
11.2.6 Down-Titration Phone Call

Recording of Adverse Events.

Reminder of appointment for the next visit according to the schedule described in
Section 5.2.
11.2.7 Final Visit (FV following a Study Drug Free Period after an EDV or FV initiated 
upon Sponsor request at the end of the program)

Vital signs including blood pressure and pulse.

Body weight and height (only for those subjects still potentially growing).

Physical and neurological examination.

ECG (except after an EDV when EDV ECG results were normal).

Retrieval of previous subject DRC.

Recording of seizures.

Recording of workdays and school days lost and days subject received help from a 
caregiver (paid or not) at home during the first 2 years.

Hospital stay during the first 2 years.
REDACTED 
ect me
ACT
ect me
COPY
prot
PY 
prot
nd day
COPY
nd day
This document

e

P
t 
P

m

cannot 
Vital si
anno
Vital si
Bod
can
Bod
be
on Sp
be 
on Sp
used 
Visit 
sed
Visit (
d
(
Spo
u
Spo
to 
port
Even
port 
Even
sup
ntment
uppo
ntment
any 
Ca
y
Ca
t
a
t
marketing 
all
m
all
authorization 
y
n
ys s
n
s s
ent
th
entall
thor
ally
r
y
application
n at th
tion 
n at th
ocol
ppl
ocol
subj
ap
subj
and 
xcept
and
xcept
any
at th
any 
at th
extensions 
e first
tens
e first
ept fo
exte
pt fo
h
e
h
or
udy
or
udy
r 
y
r
y
variations 
v
o
v
o
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 49 of 72

Healthcare provider consultation not foreseen by protocol during the first 2 years.

Laboratory assessment including safety (hematology, blood chemistry, and urinalysis), 
urine pregnancy test (if applicable).

Recording of Adverse Events.

Assessment of suicidality (C-SSRS).

Medical procedures.

Concomitant medications (AED and Non-AED) documentation.

Drug return/accountability including study medication intake and compliance check.

Completion of end of study status.

Retrieval of “Clinical Study Subject Card”.
11.2.8 Additional Visit
At any time, the subject may have an additional study visit/phone call if the Investigator or 
the subject deems it necessary. All information, including reason for visit/phone call, any 
information on AEs, etc., should be collected in the source documents and recorded in the 
appropriate section of the CRF.  Study medication can be dispensed if required.
11.3
Handling of Biological Samples
The safety samples (hematology, biochemistry, urinalysis, pregnancy test) will be routinely 
assayed and the results sent by fax and letter to the Investigators as specified in 
Section 11.1.14.
11.4
Other Supplies
Not applicable.
12
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS
12.1
Adverse Events
12.1.1 Definition of Adverse Event (AE)
An adverse event is any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product which does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.
In order to ensure complete safety data collection, all AEs or undesirable experiences 
occurring during the study (i.e., after signature of the Informed Consent), including any pre-
REDACTED 
hemis
EDA
hemis
nd le
RED
nd le
COPY
sourc
PY 
sourc
n can b
COPY
n can b
This document
subje
ent 
subje
rela
men
rela
m
cannot 
Def
t
Def
adver
can
adver
ec
c
ec
be 
finit
be
finit
used
rse Ev
sed 
rse Ev
to support 
EVEN
sup
EVEN
any marketing
etter t
ing 
etter t
authorization 
be 
n
be 
try
aut
try, u
uth
, u
t
a
t
application 
ne call
tion
ne call
ason fo
licat
ason fo
e docum
pplic
e docum
e disp
ap
disp
and any extensions 
check
nsion
check
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 50 of 72
and post-Treatment Periods required by the protocol, must be reported even if no 
investigational product was taken but specific study procedures were conducted. These 
include all AEs not present prior to the initial visit and all AEs which recurred or worsened 
after the initial visit.
Signs or symptoms of the condition/disease for which the investigational product is being 
studied should be recorded as AEs only if their nature changes considerably or their 
frequency or intensity increases in a clinically significant manner as compared to the clinical 
profile known to the Investigator from the subject’s history or the baseline period.
12.1.2 Procedures for Reporting and Recording Adverse Events
The study participant will be given the opportunity to report Adverse Events spontaneously. 
A general prompt will also be given to detect adverse events, e.g.,
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self-assessment procedures (e.g., diary cards) 
employed in the study.
12.1.3 Description of AEs
The following guidelines and definitions should be used by the Investigator for the 
description of an AE when reporting information:
Nature of the AE:
Preferably an overall diagnosis or syndrome, rather 
than individual symptoms or signs. The Investigator
must report adverse events using standard medical 
terminology. The CRF and source documents should 
be consistent. Any discrepancies between the 
subject’s own words on his/her own records (e.g., 
diary card) and the corresponding medical 
terminology should be clarified in the source 
documentation.
Date of onset:
Date the AE started.
Pattern:
Intermittent
The AE recurs with the same intensity at various 
intervals throughout the entire time period specified. 
There were intervals within the specified time period 
when the AE was not present.
Continuous
The AE is present at the same intensity for the entire 
time period specified. There was no time at which the 
event abated or was not present during the time period 
specified.
REDACTED 
ions sh
REDA
ions sh
g inf
RE
g inf
COPY 
al
Y
al
elf
CO
elf-
CO
-f-f
CO
f-f as
CO
as
This document cannot
of on
ot 
of on
tern:
nno
tern:
be 
ns
b
ns
used to support any marketing 
ho
g
ho
format
ting
format
Pre
ar
Pre
authorization
sessm
on 
sessm
ould
au
ould
application 
,
o
,
since y
plica
since y
me
a
me
and
e Eve
and 
e Eve
any extensions 
he clin
sions
he clin
od.
en
od.
or 
g
o
g
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 51 of 72
Intensity:
Mild
The subject is aware of the sign or symptom 
(syndrome), but it does not interfere with his/her 
usual activities and/or it is of no clinical consequence.
Moderate
The AE interferes with the usual activities of the 
subject or it is of some clinical consequence.
Severe
The subject is unable to work normally or to carry out 
his/her usual activities, or the AE is of definite 
clinical consequence.
Action taken with investigational product:
Not applicable
For AEs occurring during the study drug free period.
No change
Investigational product dosing remained the same in 
spite of the AE being present.
Dosage increased
Investigational product dose was increased because of 
this AE.
Dosage decreased
Investigational product dose was decreased because 
of this AE.
Temporarily discontinued
Investigational product was temporarily discontinued 
because of this AE, either because the subject chose 
to discontinue the study drug or the physician felt it 
was in the subject’s best interest to temporarily 
discontinue the investigational product.
Permanently discontinued
Investigational product was permanently discontinued 
because of this AE, either because the subject chose 
to discontinue the study drug or the physician felt it 
was in the subject’s best interest to discontinue the 
investigational product.
Other actions taken:
If action taken other than study drug, the appropriate 
sections should be completed: Medications, Medical 
procedures.
Outcome:
Resolved
The AE is no longer present at any intensity -
completely abated.
Resolved with sequela
The AE is resolved but residual effects are still 
present.
Ongoing
The AE is still present at the last contact with the 
subject. If the AE is marked “ongoing”, the outcome 
date should be blank.
Worsened
The AE is still present but at a heightened intensity. 
The rule of repetition of AE reporting should be 
applied.
REDACTED
gation
ED 
gation
use of
CTE
use of
disco
DAC
disco
was i
RED
was i
di
R
di
COPY
al prod
OPY 
al prod
C
This document cannot 
Re
nno
Re
be
solv
be 
solv
used 
u
to support any marketing 
n 
g
n 
iscontin
eting
iscontin
Inves
rket
Inves
be
ar
be
authorization 
al pro
zatio
al pro
f this A
horiz
f this A
ontinu
utho
ontinu
th
au
the
au
e
application 
nt.
on
nt.
dose wa
catio
dose wa
duct do
app
duct do
and 
dy
d
dy
d
y
d
y
rema
and
rema
any 
drug
any
drug
extensions 
carry
sion
carry
finite
ensi
finite
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 52 of 72
Fatal
This AE caused or directly contributed to the 
subject’s death.
Date of outcome:
Date the AE abated.  If the AE consists of several 
signs and symptoms (syndromes), the sign or 
symptom with the longest duration determines the 
duration of the AE.  If the AE is marked “ongoing”, 
the outcome date should be blank.
Relationship to study drug:
None
Only applicable when no investigational product was 
taken or when the subject is taking single-blind 
placebo, or when the AE can be ascribed with 
reasonable certainty to another cause (e.g., a gun shot 
wound).
Unlikely
There are good reasons to think that there is no 
relationship (e.g., the AE is a known adverse drug 
reaction of a concomitant medication).
Possible
Equally valid arguments can be considered for or 
against an implication of the investigational product, 
For example, the AE:

follows a reasonable temporal sequence from the 
administration of the investigational product.

follows a known or expected response pattern to 
the investigational product.

but could readily have been produced by a number 
of other factors.
Probable
The relationship is likely. For example, the AE:

follows a reasonable temporal sequence from 
administration of the investigational product.

follows a known or expected response pattern to 
the investigational product.

is confirmed by improvement on stopping or 
reducing the dosage of the investigational product.

could not be reasonably explained by the known 
characteristics of the subject’s clinical state.
REDACTED 
lly
CT
lly val
CTE
val
y
CT
y
ainst a
DACT
ainst a
For e
REDA
For e

R

COPY
ea
Y
ea
e.g., th
OPY 
e.g., th
a con
COP
a con
This document cannot be used to support any marketing 
exa
g
exa
follo
ting
follo
ad
et
ad

a

authorization
ncom
ion 
ncom
alid arg
oriza
alid arg
an im
utho
an im
amp
au
amp
application 
ns to thi
plica
ns to thi
he AE 
app
he AE 
mita
a
mita
and
sc
d
sc
cause
and 
cause
any
ngle
ny 
ngle
cribed
any
cribed
extensions
ng”
ns 
ng
al prod
exte
al prod
le-
e
le-
or 
”
o
”
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 53 of 72
Highly probable
There is a strong relationship. For example, the AE:

follows a reasonable temporal sequence from 
administration of the investigational product.

follows a known or expected response pattern to 
the investigational product.

is confirmed by improvement on stopping or 
reducing the dosage of the investigational product, 
and reappearance on repeated exposure (re-
challenge).
12.1.4 Follow-up on Adverse Events
If an AE is still ongoing at the time the CRF is collected, a follow-up report should be 
provided at a later date. If no follow-up report is provided, the Investigator must provide a 
justification.
The Sponsor may request that the Investigator perform or arrange for the conduct of 
supplementary measurements and/or evaluations (e.g., re-challenge procedure).
A serious AE or an AE leading to premature discontinuation from the study must always be 
followed up until it has resolved or the Investigator no longer feels it is clinically significant.
12.1.5 Rule for Repetition of an AE
An unexpected increase in the intensity of an AE should lead to the repetition of the AE 
reporting with:

the outcome date of the first AE that is not related to the natural course of the disease 
being the same as the start date of the repeated AE.

the Investigator’s original description of the AE being the same for the first and repeated 
AE.
12.1.6 Pregnancy
Should a subject become pregnant during the course of the study, the SP of the Sponsor 
should be informed immediately. The subject should be excluded from the study as soon as 
pregnancy is known (immediate start of down-titration of investigational product intake).
The pregnancy will be documented in the AE section of the CRF. The Investigator must 
inform the subject about the potential risk of malformations that may be caused by any AED, 
and about the available alternatives, eg, voluntary termination with medical indication.  The 
progression of the pregnancy must be followed up using the standard Sponsor Pregnancy 
form. The Investigator has to report on the health of the mother and of the offspring.
REDACTED
ons (
ED 
ons (
mature 
DAC
mature 
he 
RE
he Inv
ED
Inv
COPY 
erform
CO
erform
C
This document 
hou
nt
hou
pre
men
pre
cannot t
uld a s
cann
uld a s
uld
ca
uld
be
egna
be 
egna
used to
r
t
r’s o
to 
’s o
support 
he firs
por
he firs
the sta
supp
the sta
orig
s
orig
any
inten
ny 
inten
marketing 
vest
g
vest
E
a
E
ns
m
authorization
m or 
tion 
m or 
e.g., re
izatio
e.g., re
disco
utho
disco
stig
au
stig
application
w
io
w-up 
ion 
-up 
e 
c
e Inves
catio
Inves
and 
a
any extensions 
or 
n
or 
al prod
sion
al prod
re (re-
tens
re (re-
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 54 of 72
In cases where the partner of a male subject enrolled becomes pregnant, UCB will ask the 
Investigator or designee to contact the subject and his partner to request consent via the 
Partner Pregnancy Consent Form where legally acceptable.  If the partner agrees to provide 
additional information, the Pregnancy Report and Outcome form will be forwarded to the 
subject’s partner for completion.
12.1.7 Overdose of Investigational Product
For this protocol, any daily intake of more than 200 mg/day will be considered as an 
overdose. Symptoms associated with an overdose must be recorded as AEs. Overdose 
without signs or symptoms will be documented in the “Study Medication Intake” section of 
the CRF.
12.2
Serious Adverse Events
12.2.1 Definition of Serious Adverse Event (SAE)
A Serious Adverse Event is any untoward medical occurrence that occurs at any dose:

results in death.

is life threatening, (an immediate risk of death).

requires in-patient hospitalization or prolongation of existing hospitalization.

results in persistent or significant disability/incapacity (any severe or long-lasting inability 
to carry out normal work or normal activities).
or

is a congenital anomaly/birth defect (in a child of a subject/patient who took the 
investigational product, especially of a mother who was pregnant during the study).
In this context, the term life threatening refers to an event in which the subject was at 
immediate risk of death at the time of the event; it does NOT refer to an event which might 
have caused death if it would have been more severe.
Any important medical event that may not be immediately life threatening or result in death 
or hospitalization but, based upon appropriate medical judgment, may jeopardize the subject 
or may require medical or surgical intervention to prevent 1 of the other outcomes listed in 
the definition above should also be reported as a SAE. Examples of such events are intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization; or development of drug dependency or drug 
abuse.
Any event reported by the Investigator to the local authorities will follow the same reporting 
procedures as a “Serious Adverse Event”.
REDACTED
dica
ED 
dica
sk of d
DAC
sk of d
n or pr
RED
n or pr
t di
R
t di
COPY 
O
l o
C
l o
This document
he d
nt 
he d
treat
men
treat
c
m
c
cannot
pitaliz
not 
pitaliz
may
can
may re
ann
re
y
an
y
def
ca
def
be
tant 
be 
tant 
used
ath if
ed 
ath if
to
death
to 
death
f i
t
f i
support
, esp
ort 
, esp
rm life
supp
m life
h a
s
h a
any
rth de
any 
rth de
pec
an
pec
marketing 
rolo
g
rolo
disabilit
eting
disabilit
m
r
mal act
rke
al act
f
authorization 
occur
zatio
occur
death)
utho
death)
long
au
long
application and 
on
d
on
any 
s.
ny
s. O
y
O
n Inta
any
n Inta
extensions 
d as a
exte
d as a
Ov
e
Ov
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 55 of 72
Cases involving cancer as an Adverse Event could be reported as serious using the criterion 
“medically important”.
Hospitalization for diagnostic or therapeutic procedures in the absence of any associated 
Adverse Event will not be considered as a SAE, except when otherwise required by 
Regulatory Authorities. This also applies to situation of scheduled elective surgery where no 
AE is present.  Non-complicated, preplanned elective surgery will not be considered an AE or 
SAE even if it involves hospitalization. However, if a hospitalization is unplanned or is a 
result of an adverse event, this will be considered an SAE.
12.2.2 Procedures for Reporting Serious Adverse Events (SAE)
The Sponsor (or its representatives) must be informed about an SAE within 24 hours of the 
site knowing about the event (see contact details for SAEs listed in Section 2).  The 
Investigator must promptly forward to the Sponsor (or its representatives) a duly completed 
“Investigator SAE report form” provided by the Sponsor, even if the data are incomplete or if 
it is obvious that more data will be needed to make any conclusions.
Additional information (e.g., autopsy or lab reports…) should be provided to the sponsor in a 
timely fashion to ensure accurate follow-up of each case. All documents in the local 
language must be accompanied by a translation in English, or the relevant information 
included in the same document must be summarized in the SAE report form.
The Sponsor (or its representatives) will communicate safety information to the appropriate 
agency(ies) and all active Investigators, in accordance with applicable regulatory 
requirements. The appropriate IRB/IEC will also be informed by the Investigator or the 
Sponsor, as specified by the applicable regulatory requirements in each concerned country. 
Investigators are to provide the Sponsor or its representatives with evidence of such IEC/IRB 
notification.
A copy of the Investigator SAE report form and completion guide will be provided to the 
Investigator. The SAE report form has to be completed in English.
If known by the Investigator, Serious Adverse Events up to 30 days after withdrawal of study 
medication must be reported to the Sponsor, even if the Investigator is certain that they are in 
no way associated with the study drug. Adverse Events that the Investigator thinks may be 
associated with the study medication must be reported to the Sponsor regardless of the time 
between the event and the end of the study.
The reference document for the assessment of the expectedness of the SAEs is the 
Investigator’s Brochure (IB).
DACTED
eport
ED 
eport
p of ea
CTE
p of ea
nslatio
DACT
nslatio
RE
be sum
REDA
be sum
COPY
so
Y
so
an
OPY
any c
PY 
y c
ts
C
ts
This 
nt
o w
t
o w
documen
assoc
ent 
assoc
be
me
be
cannot
n b
ot
n by
ot 
y
cation
anno
cation
way
ca
way
a
be 
y t
b
y t
used
vest
ed 
vest
The S
used
The S
to 
tig
to
tig
support
ap
t
ap
de the
port 
de the
any
IRB
ny 
IRB
pplic
any
pplic
marketing 
um
g
um
will co
rket
will co
gators, 
mar
gators, 
B/IE
m
B/IE
authorization 
s…) sh
zatio
s…) sh
ach ca
oriza
ach ca
on in E
utho
on in E
mmar
au
mmar
application 
n 
o
n S
on
Se
n 
e
esentat
atio
esentat
ven if t
plica
ven if t
onclus
app
onclus
and
E with
and 
with
ec
a
ec
any extensions 
an A
s
an A
d or is 
sions
d or is 
or 
e 
r
e 
AE
or
AE
variations 
no
va
no
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 56 of 72
12.2.3 Anticipated Serious Adverse Events
The following list of Anticipated SAEs has been identified as these events are anticipated to 
occur in the population studied in this protocol at some frequency that is independent of drug 
exposure: convulsion.  This original list will remain in effect for the duration of the protocol.
The list does not change the investigator’s obligation to report all serious AEs (including 
Anticipated SAEs) as detailed in Section 12.2.2.
13
STATISTICS
A general description of statistical methods is presented below.  Additional details will be 
described in the Statistical Analysis Plan (SAP).
13.1
Statistical and Analytical Plans
13.1.1 Study Population(s)

Subpopulations
There are 2 mutually exclusive subpopulations.  They are defined based upon enrollment.
1. Partial onset seizure: Subjects enrolled from prior studies N01193, N01252, N01253, 
and subjects from N01254 with a diagnosis of POS at N01254 study entry
2. Primary generalized seizure: Subjects enrolled from prior study N01254 with a 
diagnosis of PGS at N01254 study entry
The Efficacy Population will consist of all subjects who took at least 1 dose of study 
medication and have at least 1 seizure diary during the Evaluation Period.
The Safety Population will consist of all subjects who took at least 1 dose of study 
medication.
13.1.2 Efficacy and Safety Variables
Primary safety variables:

Occurrence of a TEAE

Withdrawal due to an AE

Occurrence of an SAE
REDACTED 
ulation
DAC
ulation
ts en
RE
ts en
COPY 
This 
Prim
nt 
Prim
document
nt cannot
Eff
not
Effic
t 
ic
fif
ot
fif
mar
c
mar
be 
ca
b
ca
used
ulatio
ed 
ulatio
to 
on
to
on
support 
will co
port
will c
t least 
upp
t least 
any
1254
ny 
1254
marketing 
nrolled
ting
nrolled
ith a di
rket
ith a di
re: Sub
mar
re: Sub
4 s
m
4 s
authorization 
ns.  Th
utho
ns.  Th
application and 
o
d
on
d
n
any 
nal de
any
nal de
extensions
ding
ns 
ding
or 
g
o
g
variations 
ol.
a
ol.
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 57 of 72
Other safety variables:

Laboratory tests (hematology, blood chemistry, urinalysis)

Vital signs (systolic blood pressure [SBP]), diastolic blood pressure [DBP], pulse rate) 
and body weight

Electrocardiogram (ECG)

Physical and neurological examinations

Change in Hospital Anxiety and Depression Scale (HADS) scores from the Baseline 
of the previous study to each assessment for the first 2 years and to the last Evaluation 
Period assessment during the first 2 years
Secondary efficacy variables:
POS (type I) frequency per 28 days during the Evaluation Period
Percent reduction in POS (type I)frequency per 28 days from Baseline of the previous 
study to the Evaluation Period
Responder rate for POS (type I) frequency over the Evaluation Period. A responder is
defined as a subject with a ≥50% reduction in seizure frequency from the Baseline 
Period of the previous study
Other efficacy variables:
For subjects with focal-onset epilepsy:
Percentage of subjects continuously seizure-free for all seizure types (I+II+III) for at 
least 6 months and at least 12 months during the Evaluation Period
For subjects with generalized epilepsy:
Generalized (type II) seizure days per 28 days during the Evaluation Period
Percent reduction in generalized (type II) seizure days per 28 days from Baseline of the 
previous study to the Evaluation Period
Responder rate for generalized (type II) seizure days over the Evaluation Period. A 
responder is defined as a subject with a ≥50% reduction in seizure days from the 
Baseline Period of the previous study
REDACTED
ency
TED
ency p
D 
p
y
D
y
) frequ
REDA
) frequ
0% r
RE
0% r
COPY 
he Eva
COPY
he Eva
This document cannot
Gener
not 
Gener

c
P
ca
P
be 
w
e
w
sed 
ths
d
ths
u
with 
use
with 
to
s an
to 
s an
support
set ep
ort 
set ep
ubject
sup
ubject
d
any 
pi
a
pi
marketing
ue
g
reduct
ting 
reduct
authorization 
valu
n
valu
per 28
izat
per 28
ency
aut
ency
application 
luatio
ap
uatio
and
nd to
nd 
nd to
any 
s from
any
s from
o t
a
o t
extensions or variations 
te) 
ari
te) 
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 58 of 72
Percentage of subjects continuously seizure-free for all seizure types (I+II+III) for at 
least 6 months and at least 12 months during the Evaluation Period
The following will be evaluated separately for subjects with focal-onset epilepsy and subjects
with generalized epilepsy:
Change in Patient Weighted Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)
scores from Baseline of the previous study to each assessment for the first 2 years and 
to the last Evaluation Period assessment during the first 2 years
EuroQol 5 Dimensions (EQ-5D) questionnaire response for each assessment for the first 
2 years for the Evaluation Period and for the last assessment during the first 2 years of 
the Evaluation Period
Pharmacoeconomic variables
The following will be evaluated separately for subjects with focal-onset epilepsy and subjects
with generalized epilepsy:
Direct costs (healthcare provider consultations not foreseen by the protocol, concurrent 
medical procedures, concomitant medications, hospitalizations, and emergency room 
[ER] visits) during the first 2 years of the Evaluation Period
Indirect costs (work days or school days lost by the subject and days subject received 
help from a caregiver) during the first 2 years of the Evaluation Period
Socio-professional data for each assessment for the first 2 years and for the last 
assessment during the first 2 years of the Evaluation Period
13.1.3 Statistical Evaluation

General considerations:
Summary statistics will consist of frequency tables for categorical variables and descriptive 
statistics (number of available observations, mean, median, standard deviation, minimum, 
maximum, 25th and 75th percentiles) for continuous variables.
The periods considered are: 

Evaluation Period (V1 until the last Evaluation Visit)

Down-Titration Period

Post-Treatment Period
Efficacy summaries will be created separately for the POS and PGS subpopulations within 
the efficacy population, and safety summaries will be created for the safety population.
REDACTED 
atio
D
atio
ication
TED
ication
of the
ACT
of the
hool d
RED
hool d
the
R
the
COPY 
s w
Y
s w
ons 
CO
ons 
This document 

me

cannot 
m, 
ot
m, 
e perio
can
 perio
be
umb
be
umb
25
be
25th
e 
th
used 
stics w
sed
stics w
mber
us
mber
to 
a
support 
ion
ort
ion
ations
sup
tions
any 
2 
y
2 
marketing 
day
g
day
first 2 
eting
first 2 
ach ass
marke
ach ass
2 y
m
 year
ma
ear
authorization 
 not fo
ation
 not fo
ns, ho
rizat
ns, ho
 Eval
thor
 Eval
y
a
ys lo
au
s lo
application 
h focal
plica
h focal
and 
g
d
g
any 
ssm
y
ssm
 the f
any
 the f
extensions 
31
s
31
y
i
years a
ons
ears a
sme
ex
sme
or 
-
o
-P)
or
P)
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 59 of 72

Baseline:
Baseline, whether efficacy or safety, will always refer to the original prior study pretreatment 
Baseline value.  Baselines created and validated, as part of the prior study SAPs, will be 
copied and used by this study for all changes from baseline analyses.

Study entry/disposition:
Subjects will be sufficiently described to enable a clear understanding of the populations and 
subpopulations and relevant demographics, disease, medical history, current treatment(s), as 
well as disposition.  Historical and Baseline data will be copied from the prior study as 
required by the SAP.

Seizure efficacy variables:
Analyses will be based upon the Efficacy Population.  Summaries will be over the entire 
Evaluation Period and by 3-month periods over the Evaluation Period.

QOLIE-31-P, HADS, EQ-5D, and socio-professional efficacy variables:
Analyses will be based upon the Efficacy Population and summarized by data collection 
scheduled visits and for the last Evaluation Period assessment during the first 2 years. Data 
collected after Year 2 are not planned to be summarized.

Medical resource and indirect cost efficacy variables:
Analyses will be based upon the Efficacy Population and summarized by 3-month periods.  
Data collected after Year 2 are not planned to be summarized.

Safety variables:
Analyses will be based upon the Safety Population.  Summary tables will be presented over 
the Evaluation Period by time windows, by periods, and by categories of total duration of 
exposure.
Treatment-emergent AEs will be summarized by categories of total duration of exposure, 
period, and Medical Dictionary for Regulatory Activities (MedDRA®) Primary System Organ 
Class (SOC), and Preferred Term in incidence tables.  Separate tables will be provided by 
categories of total duration of exposure, for AEs leading to withdrawal from the study, and 
for SAEs.
REDACTED 
io
CT
io-
CT
-pro
CTE
pro
ficacy
RED
ficacy
D
ua
R
ua
COPY 
on.  Su
OPY
on.  Su
he Ev
CO
he Ev
This document 
Trea
men
Trea
p
m
p
cannot
aluati
not 
aluati
osure
can
osure
be
will b
be 
will b
used
ables:
sed 
ables:
to support 
upon th
ppor
upon th
Year
sup
Year 2 a
pp
2 a
any
ect c
any 
ect c
marketing
Pop
g 
Pop
ation Pe
eting
ation Pe
ed to be
arke
ed to be
authorization
valua
tion 
valua
ofessi
horiz
ofessi
opu
au
opu
application 
ummar
app
mmar
ti
and 
he 
d
he 
any
nt tr
ny 
nt tr
prio
any
prio
extensions 
popu
exte
popu
re
e
re
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 60 of 72
Laboratory values, vital signs, and weight will be summarized by period and visit.  Possibly 
clinically significant treatment-emergent abnormalities for laboratory values, vital signs, and 
weight will be listed and summarized by period and visit.  Electrocardiogram abnormalities, 
as well as physical and neurological abnormalities, will also be listed by period and visit.
Hospital anxiety and depression scales will be analyzed for the POS and PGS subpopulations.
13.2
Determination of the Sample Size
No sample size calculation has been made. Sample size will depend upon recruitment into 
and completion of preceding studies; approximately 500 - 1000 subjects are expected.
13.3
Statistical and Analytical Issues
13.3.1 Handling of Dropouts of Missing Data
Safety and efficacy variables will be analyzed as they are available. Days with missing 
information will be ignored in the calculation of the seizure frequency and seizure days.  
Since subjects will drop out at different times from the study, results will be presented by 
categories of duration of exposure.
13.3.2 Interim Analysis and Data Monitoring
Due to the single-arm open-label nature of this study, no interim analysis as such will be 
performed. However, interim database snapshots may be performed to allow safety and 
efficacy analyses in support of submission activities or to allow optimization of the 
development program. In addition, an ongoing medical review (Safety Data Review) 
applying to the entire BRV program is organized.
13.3.3
Use of an Efficacy Subset of Subjects
The efficacy population will be a subset of the safety population.  The efficacy population 
will be divided into 2 mutually exclusive groups, the POS and PGS subpopulations.  
Additionally, as needed, the POS and the PGS subjects may be subset into categories that 
group subjects and subject data according to similar BRV exposure times.
13.3.4 Examination of Subgroups
Subgroup analyses, if performed, will be specified in the SAP.
13.4
Criteria for Starting the Analysis
A pre-analysis data review will take place before starting any formal analysis.  A pre-analysis 
data review will follow pertinent UCB Standard Operating Procedures.
REDACTED 
ro
D
ro
onitori
EDAC
onitori
r
R
r
COPY 
y
PY
y are
Y
are
y
Y
y
e seiz
OPY
e seiz
om th
CO
om th
This document
3.3.
nt 
3.3.
S
m
S
ot
all
t
all
cann
subje
not 
subje
3 4
c
3 4
be
e
ly
be
ly, a
be 
, a
used
opulat
sed 
opulat
d int
use
d int
to 
f
suppor
V pro
ort 
V pro
fficacy
sup
fficacy
any
ition,
any 
ition,
ogr
a
ogr
marketing 
re of th
keting
re of th
ase
arke
ase sn
ke
sn
bmiss
ma
bmiss
authorization 
zu
zu
he stu
tion
he stu
ing
auth
ing
application 
availab
pplic
availab
ure
ap
ure fr
pp
fr
and any extensions 
ruitme
xtens
ruitme
expe
ext
expe
or 
ion
or
ion
variations 
ons.
va
ons.
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 61 of 72
13.5
Dictionaries
Adverse events medical and surgical history will be coded according to the MedDRA.  
Coding of indications of concomitant medication has been stopped during the course of the 
study.
Medications will be coded according to WHO Drug dictionary.
14
ETHICS AND REGULATORY REQUIREMENTS
14.1
Approval
The final protocol and any amendments must be signed by the Principal Investigator of the 
site, the Sponsor Study Physician, the Sponsor Clinical Lead, the Sponsor Clinical Trial 
Manager (CTM) and the Sponsor Statistician.
The final protocol must be submitted to and approved by:

a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board 
(IRB).

the relevant Regulatory Authorities, according to local regulations.
If any alterations to the protocol are required by these bodies, they can be implemented only 
with the written agreement of the Investigator, the Study Physician, the Clinical Lead, the 
Statistician, and CTM, and the sponsors’ approvers before further submission to the 
requesting body.
A copy of the IEC/IRB’s written approval with clear identification of the submitted 
document(s) and a list of members attending the meeting (listed by function and affiliation) 
should be forwarded by the Investigator to the CTM. 
The usual composition of the IRB/IEC (or DHHS number) along with an IRB/IEC Statement 
of Compliance should also be forwarded to the CTM.
Before submission to an IRB/IEC, the consent form and any other written information to be 
provided to subjects (e.g., advertisement) must be submitted for internal Sponsor approval. 
The study is not allowed to start until the protocol and related documents (informed consent, 
advertisement, etc.) have received written approval from the IEC/IRB and Regulatory 
Authorities, if applicable, as well as until other GCP prerequisites are fulfilled. If new 
information becomes available, it should be communicated without delay to the subject, the 
Investigator, the IEC/IRB, and regulatory authorities, wherever required.
REDACTED
mmit
ED 
mmit
, accor
DAC
, accor
req
R
req
COPY 
roved 
COP
roved 
tt
C
tt
This 
nt 
rov
nt
rov
documen
The 
ment
The 
ad
m
ad
cannot 
re sub
anno
re sub
vide
ca
vide
be
ance 
be 
ance 
used 
mposi
use
mposi
u
to
d b
to
d by
o 
y
support 
s writte
port
s writte
t of me
supp
t of me
b
s
by t
s
y th
u
h
any marketing 
quired 
eting
quired 
vestiga
rket
vestiga
onsors
mar
onsors
authorization 
by
ion
by:
n
:
tee (IE
zatio
tee (IE
rding 
utho
rding 
application
incip
on 
incip
he 
ati
he Spo
tio
Spo
and 
pa
a
pa
any extensions or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 62 of 72
The IEC/IRB must be notified promptly by the Investigator (or Sponsor, if applicable) in 
writing of the following:

Deviations from, or changes to the protocol to eliminate immediate hazards to all the 
study subjects.

Significant changes to the conduct of the study. Significant changes to the protocol can 
only be affected by a formal protocol amendment that must be submitted to the IEC/IRB 
and approved prior to implementation at the site.

New information that may adversely affect subject safety or the conduct of the study.
The Investigator (or Sponsor, if applicable) should comply with the applicable regulatory 
requirements related to the reporting of safety information to the IEC/IRB and Regulatory 
Authorities.
14.2
Subject Information and Consent
The original Informed Consent form can be amended as appropriate.  If the Informed Consent 
form is amended during the study, the Investigator (or the Sponsor, if applicable) must follow 
all applicable regulatory requirements pertaining to the approval of the amended Informed 
Consent form by the IRB/IEC and use of the amended form.
All studies conducted at centers in the United States must include the use of a Health 
Insurance Portability and Accountability Act Authorization form.
Adequate information will be provided to the subject in both oral and written form and 
consent will be obtained in writing prior to performance of any study specific procedure. The 
content and process of obtaining informed consent will be in accordance with all applicable 
regulatory and IEC/IRB requirements.
For subjects already ongoing in the study, a new informed consent will be issued and need to 
be signed covering the increased risk of suicidality or suicidal thoughts to comply with the 
warning issued by the FDA subsequent to analysis performed on marketed anti-epileptic 
drugs.  Although data from BRV studies were not included in FDA’s analysis, this risk may 
be expected because BRV belongs to this class of medication.
The Sponsor may provide a sample informed consent form and a subject information sheet. 
The final consent form must be approved by the IEC/IRB and should contain the applicable 
ICH-GCP elements in a language readily understood by the subject (i.e., lay terminology).
The Investigator, or a person designated by the Investigator, should fully inform the subject 
about all pertinent aspects of the study including the fact that the protocol has been granted 
the approval of the IRB/IEC and local regulatory authorities if required.
REDACTED
g
amen
ED 
amen
United
DAC
United
ility
RED
ility A
ED
A
y
ED
y
COPY 
as 
Y
as 
(or th
OPY
(or th
to th
CO
to th
C
This 
nt 
he 
nt
he 
documen
ICH
ment
ICH
cannot 
Spons
ann
Spons
e fin
ca
 fin
be
d be
be 
d be
sed
b
e
by th
ed 
y th
u
ugh d
use
ugh d
u
to
the 
to 
the 
he
t
he
support 
quir
rt
quir
ongoing
supp
ongoing
e in
s
e in
any
ng in
ny 
ng in
rem
an
rem
keting 
Act
g
Act
mark
ded to t
arket
ded to t
g prior
mar
g prior
fo
m
f
authorization
he app
tion 
he app
ded fo
zatio
ded fo
d State
utho
d State
t Au
au
t Au
application 
propria
pplic
propria
e Spon
app
e Spon
and any
and
ny 
and
extensions 
e stu
sion
e study
on
dy
le reg
exte
le reg
d R
e
d R
or 
o
RB
r
RB
variations 
n
v
n
RB
va
RB
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 63 of 72
Subjects will be informed of the purpose of the study in unambiguous language they easily 
understand. Their participation is voluntary and they can at any time decide to stop their 
participation without any influence on their future care or treatment. The subjects must be 
informed about the main procedures used to guarantee their anonymity, especially during the 
analysis of their personal data. They will receive complete written information in the Subject 
Information Sheet. Subjects should be able to ask any questions about the study and to 
receive relevant answers.
After having received extensive information about the purpose and risks of the study and 
having had enough time to consider participation in the study, the subject or their legal 
representative must give their written consent by signing and dating the Informed Consent 
Form. This form will also be signed and dated by the person who obtained the informed 
consent and then retained by the Investigator. Obtaining of consent will be confirmed in the 
subject’s medical records.  The subject will receive a copy of the signed and dated consent 
form and the original will be filed in the Investigator’s Study File. The consent form or a 
specific assent form, where required, will be signed and dated by minors.
If the signature of a witness is required, the witness should sign and personally date the 
consent form after the subject has signed. By signing the consent form, the witness attests 
that the information in the consent form and in any other written information was accurately 
explained to, and apparently understood by, the subject and that informed consent was freely 
given by the subject.
The subject may withdraw their consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the informed consent form. A 
Case Report Form must not be started, nor may any study specific procedure be performed 
for a given subject, without obtaining his/her written consent to participate in the study.
If any new information that could influence the subject’s decision to stay in the study 
becomes available, this information will be transmitted to the subject without delay. In 
addition, the informed consent form must be amended accordingly or a separate consent form 
be created and submitted to the IEC/IRB for approval prior to being implemented for
re-consent of all ongoing subjects in the study and for use in consenting all subjects entering 
the study from that point forward.
14.3
Subject Confidentiality
Subject confidentiality will be maintained at all times. Personnel from the Sponsor (or its 
representative) from Regulatory Authorities and members of the IRB/IEC may inspect 
medical records and Case Report Forms for verification of the accuracy of data. These 
groups are obliged to respect medical confidentiality and to refrain from divulging the 
subject’s identity or any other personal information. Sites will be required to obliterate any 
REDACTED
sign
ED 
sign
nd in a
CTE
nd in a
b
DA
by, th
DACT
y, th
COPY 
nd
Y
nd
e
C
ess sh
COP
ss sh
nin
C
nin
This document 
.3
t
.3
Su
me
Su
canno
y
o
y fro
ot 
fro
y
o
y
3
c
3
be
of a
be 
of a
om
b
om
used
orme
ed 
orme
d subm
used
d subm
ll
u
ll
to
this
to 
this
med
to
med
support 
ob
t
ob
n that c
upp
n that c
is in
su
is in
any
start
ny 
start
btain
any
btain
marketing 
sent to 
rket
sent to 
y
m
y when
mar
when
y
m
y
rted
m
rted
authorization
hould
ion 
hould
ng the
zatio
ng the
any
ori
any oth
oriza
oth
y
ori
y
he sub
utho
he sub
application
sign
on 
sign
ile.
atio
ile. T
o
T
ed b
plica
ed by m
ca
y m
d s
a
d s
and
in
d
in
will b
and 
will b
ned
a
ned
any 
orm
y
orm
ed th
any
ed th
extensions 
study
ensi
study
i
their l
exte
their l
me
e
me
or variations 
ect 
ar
ect 
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 64 of 72
possibly identifying information (e.g., name, social security number, address, etc.) on any 
materials, forms, or report prior to sending them to the sponsor or its designee.
Medical records will be handled by professional standards and existing local laws.
14.4
Informing the General Practitioner (or Pediatrician)
If the subject agrees, the Investigator may inform the subject’s regular physician of his/her 
participation in the study.
15
STUDY MANAGEMENT AND ADMINISTRATION
15.1
Monitoring
Monitoring of the study is the responsibility of the Sponsor and may be delegated to a CRO 
or a contract monitor. The Monitor (the individual responsible for monitoring) will advise 
the Investigator regarding the practical conduct of the study and maintaining compliance with 
the protocol, GCP, and all applicable regulatory requirements.
The Investigator will allow the Sponsor or its representatives to review periodically, at 
mutually convenient times during the study and after the study has been completed, all CRFs 
and corresponding source documents (e.g., portions of office, hospital and laboratory records 
for each study participant). Therefore, the monitor will have direct access to these records.
The monitoring visits provide the sponsor or its representatives with the opportunity to 
evaluate the progress of the study, to verify the accuracy and completeness of CRFs, ensure 
that all protocol requirements, applicable authorities’ regulations and Investigator’s 
obligations are being fulfilled, and resolve any inconsistencies in the study records.
If the monitoring and/or auditing process identifies serious and/or persistent non-compliance 
by an Investigator/Institution, the Sponsor may terminate the Investigator’s/Institution’s 
participation in the study.
15.2
Direct Access to Source Data/Documents
The Investigator(s)/Institution(s) will permit study-related monitoring, audits by or on behalf 
of the sponsor, IEC/IRB review, and regulatory inspection(s), providing direct access to 
source data/documents.
Source documents are original records in which raw data are first recorded. These may be:
hospital/clinic/GP records, charts, diaries, x-rays, laboratory results, printouts, pharmacy 
records, care records, ECG or other printouts, completed scales, etc. Source documents 
should be kept in a secure, limited access area.
REDACTED 
its rep
CTE
its rep
ud
DA
udy an
DACT
y an
 (e.g.,
REDA
 (e.g.,
re, t
RE
re, t
COPY
sp
Y
sp
he stu
OPY 
he stu
requir
COP
requir
This 
nt
t
t
t
documen
sourc
ent 
sourc
cannot 
Invest
anno
Invest
he
ca
he s
a
s
be
irec
be 
irec
used
the s
ed 
the s
t
u
t
to
nsti
to 
nsti
stu
to
stu
support 
ed,
t
ed,
or audi
upp
or audi
titut
su
titut
any
appli
ny 
appli
, and
any
, and
marketing 
, p
g
, p
the mo
ting
the mo
onsor o
rket
onsor o
, to ver
mar
 to ver
lica
m
lica
authorization
reme
ion 
reme
presen
oriza
presen
nd aft
utho
nd aft
porti
au
porti
application 
d may
atio
d may
ible fo
plica
ible fo
dy
ap
dy and
app
and
ap
ent
a
ent
and any extensions 
f his/h
sions
f his/h
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 65 of 72
Original laboratory results, ECG tracing and reports, DRC, PRO booklets, etc., will be 
inserted in the CRF and are also to be considered as source data.
All source documents must be, accurate, clear, unambiguous, permanent and capable of being 
audited.  They should be made using some permanent form of recording (ink, typing, 
printing, optical disc). They should not be obscured by correcting fluid or have temporary 
attachments (such as removable self-stick notes).  Photocopies of case report forms are not 
considered acceptable source documents. Photocopies will only be considered as acceptable 
source documents when used to establish permanent documentation of data captured on
non-permanent media.
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (e.g., ECG reports). Once printed, these copies should be signed and 
dated by the Investigator and become a permanent part of the subject’s source documents. 
The Investigator will authorize the monitor to compare the content of the printout and the 
data stored in the computer to ensure all data are consistent.
For subjects exposed to investigation product(s), the minimum requirements for source 
documents used in clinical studies are that they should contain the identity of the subject and 
study related identifiers (such as treatment numbers, CRF number, or similar), they should 
mention the subject’s participation in the study and identification of that study (study title or 
number), they should record the obtaining of consent (date of consent), the subject’s medical 
history, the concomitant medication treatments and dates (including contraceptive treatment), 
AEs and SAEs and the dates of the visits. The source documents should provide evidence 
that inclusion/exclusion criteria have been met. Information recorded in the CRF must be 
consistent with entries in the source documents. The monitor will perform source documents 
verification (SDV) according to the SDV plan prepared for the study.
15.3
Audit and Inspection
The Investigator will permit study-related audits by auditors mandated by the Sponsor and 
inspections by domestic or foreign regulatory authorities, after reasonable notice. The 
purposes of an audit or inspection is to confirm that the rights and well-being of the subjects 
enrolled have been protected, that enrolled subjects (i.e., signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of 
the investigational product have been processed and reported in compliance with the planned 
arrangements, the protocol, facility and IEC/IRB SOPS, ICH/GCP and applicable regulatory
requirements. The Investigator will provide direct access to all study documents, source 
records and source data. If an inspection by a regulatory authority is announced, the 
Investigator will immediately inform the Sponsor.
15.4
Case Report Forms (CRF)
REDACTED
ey
ED
ey sh
ED 
sh
y
ED
y
numb
CTE
numb
e stud
DACT
e stud
ining 
REDA
ining 
trea
RE
trea
COPY 
s
Y
s
the
CO
the m
OP
m
ho
C
ho
This 
nt
e i
t
e i
documen
arran
ment 
arran
re
me
re
canno
d hav
ot 
d hav
y
a
y proc
anno
proc
y
a
y
inve
ca
inve
be
f an 
be 
f an 
ve
b
ve
used
wil
ed 
wil
y dom
used
dom
y
a
u
a
to 
ll p
to
ll p
support 
g 
t
g 
nspecti
supp
nspecti
any
urce
ny 
urce
to th
any
to th
marketing 
of
g
of
atment
ting
atment
isits.
ket
isits. T
ave bee
mar
ave bee
e d
m
e d
authorization
minim
ion 
minim
ould co
zatio
ould co
bers, C
oriza
bers, C
dy
ut
dy and
utho
and
y
ut
y
f con
au
f con
application
ject’
on 
ject’
ntent of
atio
ntent of
mu
a
mu
and
y 
d
y 
es sho
and 
es sho
’s
a
’s
any 
must
any
must
extensions
re n
ns 
re n
accept
sions
accept
tured 
ensi
tured 
or 
ry
or
ry
not
or
not
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 66 of 72
Data reflecting participant experience with the drug(s) under investigation will be reported to 
the Sponsor. These data will be recorded on the CRF. The CRF is essentially a data entry 
form and may not routinely constitute the original (or source) medical record. CRFs should 
be kept in a secure, limited access area.
The CRF will be organized in Yearly Books. CRFs will be signed and dated by the Principal 
Investigator as indicated.
The Investigator’s or Principal Investigator’s signature on the CRF attests to its accuracy and 
completeness. Paper CRFs will be completed in dark ballpoint pen, and must be legible. If 
an entry in a CRF needs to be changed, the correction will be made as follows:

Draw a single line through the incorrect entry.

Enter the correct data, explain the correction (if necessary), date and initial the change. 
Correcting fluid, erasure or any form of obliteration of data in CRFs is not permitted 
except to obliterate information that could specifically identify a subject (i.e., a name 
written on a subject diary).
The Sponsor cannot interpret a blank answer as “NONE” or “N/A”; therefore, all fields must 
be completed. If the data are not available, a straight line should be drawn through all 
applicable fields.
Data reported in the CRF, which are derived from source documents, should be consistent 
with the source documents or the discrepancies should be explained in those source 
documents.
The Investigator must submit to the Sponsor or its representatives a completed CRF for each 
participant exposed to the investigational product.
All supportive documentation submitted to the Sponsor in addition to the CRF, such as 
laboratory results or hospitalization records, must be clearly identified with the study number, 
subject’s number, subject’s initials and visit number where relevant; any personal 
information, including the subject’s name, must be removed or rendered illegible to preserve 
individual confidentiality. All original laboratory reports will remain at the study site.
Copies of the reports will be placed in the CRF binder (where directed) and forwarded to the 
sponsor.
15.5
Adherence to Protocol
The Investigator/Institution should conduct the study in compliance with the protocol agreed 
to by the Sponsor and, if applicable, by the appropriate regulatory authority(ies) and which 
has been approved by the IEC/IRB. The Investigator/Institution and the Sponsor should sign 
the protocol to confirm agreement.
REDACTED
strai
ED 
strai
derive
RED
derive
scre
R
scre
COPY 
“NON
CO
“NON
C
This document 
15.5
ent
15.5
cannot
of 
not
of th
ot 
th
sor
ann
sor.
n
.
be
conf
be 
conf
h
b
h
used
er, 
ed
er, su
ed 
su
nclud
use
nclud
fi
u
fi
to
r ho
to 
r ho
ub
to
ub
support 
nve
rt
nve
entatio
supp
entatio
osp
su
osp
any
o the
ny 
o the
estig
an
estig
marketing 
ved 
g
ved 
epancie
eting
epancie
e S
m
e S
authorization
NE” o
tion 
NE” o
ght lin
zatio
ght lin
d fro
au
d fro
application
n CRF
ion 
n CR
ntify
catio
ntify a 
io
a 
y
io
y
a
and 
and in
and
and in
RF
a
RF
any
ows
ny 
ows
extensions 
accur
ensi
accur
t be le
exte
t be le
s:
e
s:
or 
cip
or
cip
variations 
pal
va
pal
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 67 of 72
The Investigator should not deviate from the protocol. However, the Investigator should take 
any measure necessary in deviation from or not defined by the protocol in order to protect 
clinical study subjects from any immediate hazard to their health and safety. In this case, this 
action should be taken immediately, without prior notification of the regulatory authority, 
IRB/IEC or sponsor. After implementation of such measure, the investigator must notify the 
CPM of the sponsor within 24 hours and follow any local regulatory requirements. 
Significant changes to the protocol will ONLY be made as an amendment to the protocol and 
must be approved by the Sponsor, the IRB/IEC and the appropriate regulatory authorities, if 
applicable prior to being implemented.
Any significant protocol deviation will be documented and explained by the Investigator or 
the person designated by the Investigator and will be included in the final Clinical Study 
Report.
15.6
Investigator Site File
All documents required for the conduct of the study as specified in the ICH GCP guidelines 
will be maintained by the Investigator in an orderly manner and made available for 
monitoring and/or auditing by the Sponsor or its designee.
15.7
Data Handling
The Sponsor will be responsible for data processing.
CRF data will be entered in a validated electronic database using a Clinical Data Management 
System (CDMS). Computerized data cleaning checks will be used in addition to manual 
review to check for discrepancies and to ensure consistency of the data. An electronic audit 
trail system will be used to track all data changes in the database subsequent to the 
reconciliation of the double-entered data.  The SASsystem will be used for the statistical 
analysis of the data. Regular back-ups of the electronic data will be performed.
15.8
Termination of Study
Upon completion of the study, the monitor will conduct the following activities in 
conjunction with the Investigator, as appropriate:

Return of all study data to the sponsor or its representatives while maintaining original 
source documents.

Data clarification and/or resolution.

Accountability, reconciliation and arrangements for used and unused study drugs.

Review of site study records for completeness.

Discussion/reminder on archiving responsibilities.

Discussion of IEC/IRB requirements for study termination.

Arrangements for unused CRFs, lab supplies and any other study related supplies.
REDACTED
its d
ED 
its d
data
RE
data
COPY
y
O
y as sp
OPY 
as sp
y
O
y
rly
CO
rly ma
COP
ma
y
CO
y
de
C
de
This document 

e

D
t
D

m

cannot
ction
not 
ction
R
a
Return
anno
eturn
sou
ca
sou
be
pleti
be 
pleti
w
b
w
used 
minat
use
minat
u
to
 
t
 R
to 
R
support
anc
t
anc
to trac
port 
to trac
ouble-
upp
ouble-
Regu
su
Regu
any
d da
ny 
d da
cies a
any
cies a
marketing 
a proc
ting
a proc
dat
ma
dated e
mar
ed e
data
m
data
authorization
anne
on 
anne
esigne
zatio
esigne
application 
ecified
app
ecified
er a
a
er a
and 
na
d
na
any 
e 
y
e In
y 
In
l Clin
any
l Clin
extensions
ocol
ns 
ocol
horitie
ions
horitie
Inv
e
Inv
or 
ol an
or
ol an
variations 
e
a
e
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 68 of 72
15.8.1 Termination of Study by Sponsor
In addition, the Sponsor reserves the right to temporarily suspend or prematurely discontinue 
this study either at a single site, multiple sites, or at all sites at any time for reasons including, 
but not limited to, safety or ethical issues, inaccurate or incomplete data recording, non-
compliance, or recurrent non-compliance with respect to quality or quantity.
If the study is prematurely terminated or suspended, the Sponsor or its representatives will 
inform the Investigators/Institutions, and the regulatory authority(ies) of the termination or 
suspension and the reason(s) for the termination or suspension, in accordance with applicable 
regulatory requirement(s). The IEC/IRB should also be informed and provided with 
reason(s) for the termination or suspension by the Sponsor or by the Investigator/Institution, 
as specified by the applicable regulatory requirement(s). In addition, arrangements will be 
made for the return of all unused study drugs and other material in accordance with the 
Sponsor procedures for the study.
15.9
Clinical Study Report
The Sponsor will prepare a clinical study report in accordance with the relevant ICH 
guidelines. The report will include a thorough description of the clinical laboratory methods, 
a discussion of the results and a list of all measurements as specified in the Statistical 
Analysis Plan. This report may be included in submissions to government drug regulatory 
authorities worldwide, or used for whatever reason considered appropriate by the Sponsor. 
No information contained in the report may be used without written approval of the Sponsor.
15.10
Insurance and Liability
The Sponsor has taken out an insurance policy, for the total duration of the study, covering 
the subjects, in respect of the risks involved in this study according to this protocol. In the 
case of injury or disability deriving from participation in the study, the subject is requested to 
inform the treating physician responsible for the study without delay. Information as to 
insurance policies held by the Sponsor can be made available to the Investigator and to the 
IEC/IRB upon request.
15.11
Archiving and Data Retention
The Investigator will maintain adequate records for the study including CRFs, medical 
records, laboratory results, informed consent documents, drug dispensing and disposition 
records, safety reports, information regarding participants who discontinued, and other 
pertinent data.
REDACTED 
eport 
CTE
eport 
orough
DACT
orough
of all m
REDA
of all m
nclu
RE
nclu
COPY 
This document 
.1
t
.1
Th
me
Th
canno
B up
ot 
B up
11
ca
11
be
polic
be 
polic
pon
b
pon
used
disa
ed 
disa
ating 
used
ating 
cie
u
cie
to
pect
to 
pect
sab
to
sab
pport 
ab
rt
ab
sup
n out a
upp
n out a
p
ct of 
su
t of 
any 
ility
any
ility
marketing 
me
g
me
uded in
ting
uded in
hatever
rket
hatever
eport m
mar
eport m
authorization 
in acc
oriza
in acc
h desc
utho
h desc
easu
au
easu
application
on, 
on 
on, 
al in ac
atio
al in ac
and
pro
d
pro
Inves
and 
Inves
ar
a
ar
any
nce w
ny 
nce w
ovide
any
ovide
extensions 
tatives
ensi
tatives
termin
exte
termin
e w
e
e w
or variations 
ng, 
ar
ng, 
thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 69 of 72
All records are to be retained by the Investigator until at least 2 years after the last approval of 
a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents 
should be retained for a longer period, however, if required by the applicable regulatory 
requirement(s) or by an agreement with the sponsor (ICH-GCP Guideline-Section 4.9.5).
The Investigator will contact the Sponsor for authorization prior to the destruction of any 
study records or in the event of accidental loss or destruction of any study records. The 
Investigator will also notify the Sponsor should he/she relocate or move the study related files 
to a location other than that specified in the Sponsor’s study master file.
15.12
Allocation of Responsibilities
The Investigator is responsible for the implementation of the protocol but can delegate tasks 
to the research team. The Investigator remains responsible for coordinating and informing 
his/her staff about the protocol and any possible changes made to it. The Investigator should 
maintain a site signature log of appropriately qualified persons to whom he/she has delegated 
significant study-related duties (“Delegation of Authority” document with name, function, 
signature, initials, and dates of participation in the study conduct and type of tasks delegated). 
The list should be kept up to date.
15.13
Curriculum Vitae (CV)
The Investigators should supply their updated CV (English translation), dated and signed, 
together with a list of their collaborators responsible for the practical conduct of the study.
These collaborators should also provide a recent English version of their CV, dated and 
signed.
Where applicable, a signed and dated FDA Form 1572 (in Canada, a Qualified Investigator
Undertaking Form must also be provided) is required from each Investigator showing a 
current affiliation with the research center. All sub-Investigators listed on the FDA 
Form 1572 should also date and sign a recent English version of their CVs. Any changes to 
the site personnel should be updated on a new FDA Form 1572.
15.14
Financial Disclosure
A financial disclosure statement must be obtained from each clinical site for every 
Investigator and Sub-Investigator participating in the study. These must be collected before 
subject enrollment.  The sites must inform the Sponsor if information related to financial 
disclosure changes during the course of the study and/or after study completion/end of study.
REDACTED
n the
ED 
n the
COPY
ge
Y
ge
fied 
OPY
fied pe
PY 
pe
Author
COP
Author
e s
C
e s
This document
A
en
A f
ent
fin
nt 
in
fif
nt
fif
In
me
In
cannot 
F
nno
F
be
rsonn
be 
rsonn
used
n wi
d 
n wi
ould a
used
ould a
ne
u
ne
to
mus
to 
mus
with
to
with
support 
gned a
upp
gned a
ust a
su
ust a
any
pro
ny 
pro
marketing 
r updat
rket
r updat
orators
mar
orators
ovi
m
ovi
authorization
ority
ion
ority”
n 
”
study
zatio
study
o
application
ocol 
on 
ocol
coord
atio
coord
ade to 
plica
ade to 
ersons 
app
rsons 
” d
a
” d
and 
l b
a
l b
any extensions
any
ns 
any
The 
ions
The 
dy
en
dy rela
ensi
rela
en
or 
y
o
y
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 70 of 72
15.15
Good Clinical Practice
Non-compliance with the protocol, ICH/GCP or local regulatory requirements by the 
Investigator, Institution, institution staff or designees of the Sponsor will lead to prompt 
action by the Sponsor to secure compliance. Continued non-compliance may result in the 
termination of the participants’ involvement in the study.
15.16
Publication
Subject to the provisions of the publication article of the agreement with the Investigator or 
his/her legal representative, the Sponsor will be responsible for the publication of the results 
of this study. The site shall not publish or present any research findings resulting from the 
Study or any scientific work with respect to Sponsor’s drug or its development, without the 
Sponsor’s prior written approval of the content of the presentation, manuscript or other 
materials prepared for publication. The Sponsor will respond to requests for presentation or 
publication in a timely manner and will not unreasonably withhold authorization.
16
REFERENCES
Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised 
terminology and concepts for organization of seizures and epilepsies: report of the ILAE 
Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51:676-85.
Commission on Classification and Terminology of the International League Against 
Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic 
seizures. Epilepsia. 1981;22:489-501.
Commission on Classification and Terminology of the International League Against 
Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia.
1989;30:389-99.
CPMP/EWP/566/98 rev 1 Note for guidance on clinical investigation of medicinal products 
in the treatment of epileptic disorders (EMA) 16 Nov 2000.
CPMP/ICH/2711/99 Note for guidance on clinical investigation of medicinal products in the 
paediatric population (EMA) 27 Jul 2000.
Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. 
Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. 
Epilepsia. 1998;39:81-8.
Cramer JA, Van Hammée G. Maintenance of improvement in health-related quality of life 
during long-term treatment with levetiracetam. Epilepsy Behav. 2003;4:118-23.
Engel J Jr. Report of the ILAE classification core group. Epilepsia. 2006;47:1558-68.
REDACTED 
hhalte
DACT
hhalte
zation 
REDA
zation 
Term
RE
Term
COPY
re
Y
re
onably
OPY 
onably
This document 
ram
nt
ram
Dev
ment
Dev
E
m
E
cannot 
CH/
ot
CH/
atric p
nnot
atric p
mer
ca
mer
be 
H/27
be
H/27
used
6/
ed
6/98
ed 
98
nt of
use
nt of
to 
t
support
ation a
ort 
ation 
revise
uppo
revise
y
any
89
an
89-50
ny 
-50
marketing 
n o
g
n o
minolo
ting
minolo
Termin
arke
Termin
nical a
ma
nical a
authorization 
er J, C
utho
er J, C
of se
au
of se
application
deve
on 
dev
tion, m
atio
tion, m
nd to re
plica
nd to re
withh
app
withh
and
lic
d
lic
ings re
and 
ngs re
vel
a
vel
any 
he 
ny
he In
y
In
cation
any
cation
extensions 
In
e
Inv
e
v
or 
e
r
e
variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 71 of 72
Engel J Jr, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-
Raven; 1998.
EuroQol Group. EQ-5D. A measure of health-related quality of life developed by the 
EuroQol group. User guide. 8th issue. April 2000.
Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in 
Rochester, Minnesota: 1935-1948. Epilepsia. 1993;34:453-68.
Herrmann C. International experiences with the Hospital Anxiety and Depression Scale-a 
review of validation data and clinical results. J Psychosom Res. 1997;42:17-41.
Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255-60.
Loiseau J, Loiseau P, Guvot M, Duche B, Dartigues JF, Aublet B. Survey of seizure disorders 
in the French southwest. I. Incidence of epileptic syndromes. Epilepsia. 1990;31:391-6.
Lüders HO, Acharya J, Alexopoulos A, Baumgartner C, Bautista J, Burgess R, et al. Are 
epilepsy classifications based on epileptic syndromes and seizure types outdated? Epileptic 
Disord. 2006;8:81-5.
Nasreddine W, Beydoun A, Atweh S, Abou-Khalil B. Emerging drugs for partial onset 
seizures. Expert Opin Emerg Drugs. 2010;15:415-31.
Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry. 
1996;61:433-43.
TED
415
ED
415-
D 
-
REDAC
of the e
ACTE
of the e
COPY 
lil B. 
COP
lil B. 
3
C
3
This document cannot be used to support any marketing 
rization
 Eme
ion 
 Eme
1
a
1
autho
.
at
.
epilep
thori
epilep
application 
ta J, Bu
tion
ta J, B
izure ty
licat
izure ty
erg
a
erg
and 
vey
d
vey
sia
and
sia.
n
. 1
d
1
any 
01;
y
01;
y
a
y of 
an
of 
y
a
y
extensions 
Scale
sion
Scale
;42
ex
;42
or variations thereof. 

A
Brivaracetam / N01199
CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7
Final / 15 Oct 2015 / Page 72 of 72
17
SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support 
rt any y marketing authorization application and any extensions or 
ations 
at
variat
thereof.